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Background: Cognitive impairment is a growing public health concern, and is one of the most distinctive
characteristics of all dementias. The timely recognition of dementia syndromes can be beneficial, as some
causes of dementia are treatable and are fully or partially reversible. Several automated cognitive
assessment tools for assessing mild cognitive impairment (MCI) and early dementia are now available.
Proponents of these tests cite as benefits the tests’ repeatability and robustness and the saving of
clinicians’ time. However, the use of these tools to diagnose and/or monitor progressive cognitive
impairment or response to treatment has not yet been evaluated.
Objectives: The aim of this review was to determine whether or not automated computerised tests could
accurately identify patients with progressive cognitive impairment in MCI and dementia and, if so, to
investigate their role in monitoring disease progression and/or response to treatment.
Data sources: Five electronic databases (MEDLINE, EMBASE, The Cochrane Library, ISI Web of Science and
PsycINFO), plus ProQuest, were searched from 2005 to August 2015. The bibliographies of retrieved
citations were also examined. Trial and research registers were searched for ongoing studies and reviews.
A second search was run to identify individual test costs and acquisition costs for the various tools
identified in the review.
Review methods: Two reviewers independently screened all titles and abstracts to identify potentially
relevant studies for inclusion in the review. Full-text copies were assessed independently by two reviewers.
Data were extracted and assessed for risk of bias by one reviewer and independently checked for accuracy
by a second. The results of the data extraction and quality assessment for each study are presented in
structured tables and as a narrative summary.
Results: The electronic searching of databases, including ProQuest, resulted in 13,542 unique citations.
The titles and abstracts of these were screened and 399 articles were shortlisted for full-text assessment.
Sixteen studies were included in the diagnostic accuracy review. No studies were eligible for inclusion in
the review of tools for monitoring progressive disease. Eleven automated computerised tests were assessed
in the 16 included studies. The overall quality of the studies was good; however, the wide range of tests
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assessed and the non-standardised reporting of diagnostic accuracy outcomes meant that meaningful
synthesis or statistical analysis was not possible.
Limitations: The main limitation of this review is the substantial heterogeneity of the tests assessed in the
included studies. As a result, no meta-analyses could be undertaken.
Conclusion: The quantity of information available is insufficient to be able to make recommendations
on the clinical use of the computerised tests for diagnosing and monitoring MCI and early dementia
progression. The value of these tests also depends on the costs of acquisition, training, administration
and scoring.
Future work: Research is required to establish stable cut-off points for automated computerised tests that
are used to diagnose patients with MCI or early dementia. Additionally, the costs associated with acquiring
and using these tests in clinical practice should be estimated.
Study registration: The study is registered as PROSPERO CRD42015025410.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Accuracy A measure of the closeness of the experimental value to the actual amount of the substance in
the matrix.
Area under the curve A measure of the diagnostic accuracy of a technology, which is based on the
geometric inspection of a receiver operating characteristic curve. A receiver operating characteristic curve is
a plot of the true-positive rate against the false-positive rate at different threshold settings. A technology
with perfect diagnostic accuracy will have an area under the curve of 1; a technology that is no better than
chance will have an area under the curve of 0.5; and a technology that miscategorises on every occasion
will have an area under the curve of 0.
Cut-off point See Threshold.
Diagnostic accuracy The effectiveness of a diagnostic test to correctly categorise patients as either
‘positive’ or ‘negative’. There are several ways that this can be expressed, for example as the area under
the curve or as sensitivity and specificity.
False negative When a patient has been diagnosed with, for example, mild cognitive impairment using a
standard test but the index test fails to detect this.
False positive When a patient has been diagnosed with, for example, mild cognitive impairment using
the index test but they do not have this condition.
Index test The diagnostic test that is being evaluated.
Likelihood ratio A description of how many times more likely it is that a person with the disease will
have a particular test result than a person without the disease.
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association criteria The prevalent criteria for the diagnosis of
Alzheimer’s disease, proposed by the National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders Association. These criteria require the presence
of cognitive impairment and a suspected dementia syndrome to be confirmed by neuropsychological
testing for a clinical diagnosis of possible or probable Alzheimer’s disease, while histopathologic
confirmation is needed for the definitive diagnosis. These criteria specify eight cognitive domains that may
be impaired in Alzheimer’s disease: memory, language, perceptual skills, attention, constructive abilities,
orientation, problem solving and functional abilities.
Negative predictive value The proportion of people with negative test results who do not have the
disease, for example the probability that a patient who is test negative on an index test does not have mild
cognitive impairment or dementia on clinical diagnosis.
Petersen’s criteria The criteria for mild cognitive impairment, as defined by Petersen, which include the
following: memory problems, objective memory disorder, absence of other cognitive disorders or
repercussions on daily life, normal general cognitive function and absence of dementia.
Positive predictive value The proportion of people with positive test results who actually have the
disease, for example the probability that a patient who tests positive on an index test has mild cognitive
impairment or dementia on clinical diagnosis.
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Precision Measures how close individual measurements of a sample are to each other.
Receiver operating characteristic curve A plot of the true-positive rate against the false-positive rate of
a test at different threshold settings.
Reference standard A diagnostic test used to estimate the sensitivity and specificity of another diagnostic
test, known as an index test. The reference standard is assumed to have perfect sensitivity and specificity,
and so in cases when both tests categorise something differently, the reference standard test
categorisation is assumed to be correct (either true negative or true positive).
Sensitivity Also called the true-positive rate, measures the proportion of those who actually have the
disease correctly identified with positive test results, for example the proportion of patients with mild
cognitive impairment or dementia at clinical diagnosis identified by the index test.
Specificity The proportion of people who do not have the disease, correctly identified as having a
negative test result, for example the proportion of patients without mild cognitive impairment or dementia
on clinical diagnosis who are test negative on the index test.
Threshold (clinical) A value, within a range of values, used to categorise observations into one of two
mutually exclusive groups. For example, guidelines suggest that the decision of whether or not to
investigate for possible mild cognitive impairment or dementia is influenced by cognitive test scores
(e.g. in the Mini-Mental State Examination, the threshold for mild Alzheimer’s disease is a score of 21–26,
whereas the threshold for moderate Alzheimer’s disease is a score of 10–20).
True negative In the case of mild cognitive impairment, a patient who has been correctly identified by
the index test as not having mild cognitive impairment.
True positive In the case of mild cognitive impairment, a patient who has been correctly identified by the
index test as having mild cognitive impairment.
GLOSSARY
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List of abbreviations
AD Alzheimer’s disease
AUC area under the receiver operating
characteristic curve
CAMCI Computer Assessment of Mild
Cognitive Impairment
CANTAB Cambridge Neuropsychological
Test Automated Battery
CANTAB-PAL Cambridge Neuropsychological
Test Automated Battery Paired
Association Learning
FN false negative
FP false positive
GP general practitioner
HAND HIV-associated neurocognitive
disorder
HIV human immunodeficiency virus
LR likelihood ratio
LRiG Liverpool Review and
Implementation Group
MCI mild cognitive impairment
MMSE Mini-Mental State Examination
NICE National Institute for Health and
Care Excellence
NPV negative predictive value
PPV positive predictive value
QUADAS-2 Quality Assessment Tool for
Diagnostic Accuracy Studies
TN true negative
TP true positive
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Plain English summary
The number of people who have problems with their memory and thinking is rising. The testing ofmemory and thinking is difficult and, in the early stages, the person with problems may show only
small changes.
Pen-and-paper tests are often used to test memory loss and thinking problems, alongside discussions with
health-care specialists and the individual, often in the company of their families or caregivers. Depending
on the level of memory loss and thinking problems, some people are offered treatment, whereas others
are followed up to see if their symptoms become worse. New tests to assess these problems have been
developed that are computer based and sometimes do not need a specialist to be involved.
We carried out a systematic review (a review of studies conducted by others) to look at how well these
computer-based tests diagnosed people with memory loss and thinking problems. We found limited
evidence to support the use of these computer-based tests in clinical practice without the involvement of a
health-care specialist. For this reason, at this time, we would recommend against approaches that use
computerised tests by themselves.
We also asked a person living with memory problems for their views on the results of this research.
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Scientific summary
Background
Cognitive impairment is a growing public health concern, and is one of the most distinctive characteristics
of all dementias. The timely recognition of dementia syndromes can be beneficial, as some causes of
dementia are treatable and are fully or partially reversible. Health-care professionals in the NHS currently
use a number of pen-and-paper-based tools to diagnose and monitor patients with cognitive impairment;
the Mini-Mental State Examination and the General Practitioner Assessment of Cognition are two
examples of such tests. Several automated computerised cognitive assessment tools for assessing mild
cognitive impairment (MCI) and early dementia are also now available; however, their use in diagnosis
and/or in monitoring the progression of cognitive impairment or response to treatment has not
been evaluated.
Objectives
The aim of this review is to determine whether or not automated computerised tests accurately identify
patients with progressive cognitive impairment in MCI and early in dementia and, if so, to investigate their
role in monitoring disease progression and/or response to treatment.
Methods
Search strategy
Five electronic databases (MEDLINE, EMBASE, The Cochrane Library, ISI Web of Science and PsycINFO)
were searched from 2005 to August 2015. Theses or PhD abstracts were accessed from ProQuest.
Backwards and forwards citation tracking for all relevant studies and reviews for further possible titles was
undertaken. Trial and research registers were searched for ongoing studies and reviews. After individual
tests were identified, a second search was run to identify the individual test costs and acquisition costs for
the various tools.
Study selection
The references identified were assessed for inclusion through two stages. In stage 1, two reviewers
independently screened all relevant titles and abstracts identified via electronic searching and selected
potentially relevant studies for inclusion in the review. In stage 2, full-text copies of the potentially relevant
studies were obtained and assessed independently by two reviewers. Any disagreements between
reviewers were resolved by discussion with a third reviewer at each stage. Studies that did not meet the
inclusion criteria were excluded.
Data extraction and quality assessment strategy
Data extraction forms were developed and piloted in a Microsoft Excel® spreadsheet (Microsoft
Corporation, Redmond, WA, USA) using a sample of included studies. One reviewer extracted data on
study and population characteristics and outcomes, and a second reviewer independently checked the data
for accuracy, with disagreements resolved through discussion with a third reviewer when necessary.
Evidence synthesis
The results of the data extraction and quality assessment for each study are presented in structured tables
and as a narrative summary.
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Results
The electronic searching of databases resulted in 13,352 references. An additional 5444 records were
identified through ProQuest, hand-searching and citation tracking. After deduplication, 13,542 titles and
abstracts were screened and 399 articles were shortlisted for full-text assessment. Sixteen studies were
included in the diagnostic accuracy review. No studies were identified that described automated
computerised tools used to monitor disease progression.
Owing to the heterogeneity of the included studies and the limited data available, it was not possible or
appropriate to perform any statistical analyses.
At this time, owing to the limited and poor quality of the evidence base, the use of automated
computerised tests in routine clinical practice cannot be recommended.
Conclusions
The overall quality and quantity of information currently available is insufficient to be able to make
recommendations on the clinical use of computerised tests for diagnosing and monitoring MCI and early
dementia progression.
These test scores do not always correlate with clinical history and, more importantly, with functioning.
Hence the diagnosis of patients with MCI and early dementia is based on clinical judgement and medical
history as well as the results of cognitive tests. For this reason, we would recommend against approaches
that use computerised tests in isolation at this time.
Further research is required to establish stable cut-off points for each automated computerised test used
to diagnose patients with MCI or early dementia. These cut-off points also need to be tested in specific
patient populations, for example in patients of different age groups or education levels and from different
geographical regions.
The prevalence of dementia and alternative diagnoses in the study populations should be clearly reported,
making reference to standardised checklists for diagnostic reviews such as the Standards for Reporting
Diagnostic Accuracy or the Standards for Reporting Diagnostic Accuracy – dementia.
Future research in this area should also focus on providing more information on the costs of computerised
tests, including time for training, administration and scoring of the different tests, as these are important
factors for their use in routine clinical practice. This type of information is currently lacking in the published
studies describing computerised tests used to diagnose or monitor people with MCI or early dementia.
Study registration
This study is registered as PROSPERO CRD42015025410.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Decision problem
The aim of this review was to determine whether or not automated computerised tests accuratelyidentify patients with progressive cognitive impairment and, if so, to investigate their role in monitoring
disease progression and/or response to treatment.
Specifically, the research objectives were to:
1. determine the performance of automated computerised tests in detecting mild cognitive impairment
(MCI) and early dementia
2. determine the performance of automated computerised tests in the monitoring of the disease post
diagnosis, specifically in detecting disease progression
3. identify future research needs.
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Chapter 2 Background and rationale for review
Cognitive impairment in dementia is progressive, and is a growing public health concern.1 It is one ofthe most distinctive characteristics of all dementias. Consequently, the assessment of cognitive
impairment is an essential element in the diagnosis of dementia.2
The timely recognition of dementia syndromes can be beneficial because some causes of dementia are
treatable and are fully or partially reversible, for example dementias caused by vitamin B12 deficiency,3 side
effects of medications,4 metabolic abnormality and certain brain tumours.5 There is also some evidence from
the USA that early recognition and treatment may delay the subsequent need for nursing home care and may
reduce the risk of misdiagnosis and inappropriate management.6 In the UK, the results of a recent trial
showed that patients with moderate to severe Alzheimer’s disease (AD) who continued donepezil treatment
were at reduced risk of nursing home placement.7 Early diagnosis can also assist in addressing anxiety about
changes in memory, thinking, mood or behaviour for people with suspected dementia and their carers.8
A number of pen-and-paper-based tools for cognitive assessment are currently used in the UK, for example
the Mini-Mental State Examination (MMSE) and the General Practitioner Assessment of Cognition.9 A few
automated cognitive assessment tools for assessing MCI and early dementia are now also available;
however, their use in the diagnosis and/or in monitoring the progression of cognitive impairment or
response to treatment has not been evaluated.10
The rationale for this review is to determine whether or not these automated computerised tests for
cognitive impairment have the potential to contribute to early diagnosis and simplify the current
monitoring and assessment process compared with standard NHS clinical practice.
Population
This review addresses patients in two specific diagnostic categories: those with MCI and those suffering
from early dementia.
Mild cognitive impairment
Evidence from neuropathological and neuroimaging studies suggests that biological changes associated with
dementia occur long before the onset of symptoms.11 Extensive research has been devoted to identifying the
characteristics of incipient dementia, which presents before the onset of the full dementia syndrome.12,13
This research has given rise to the concept of MCI, which is the state between the cognitive changes of
normal ageing and very early dementia.14,15 The transitional period has been described using a variety of
terms such as MCI, dementia prodrome, incipient dementia, isolated memory impairment16 and, more
recently, mild neurocognitive disorder.12 For the purposes of this report, the term ‘mild cognitive
impairment’ or MCI has been used.
Mild cognitive impairment refers to the clinical condition used to describe people whose cognitive function
is below that of the normal population for their educational level and age but who do not have any loss of
functional abilities or skills.17–20 The diagnosis of MCI is complicated by the fact that complaints of memory
loss in people over the age of 65 years are common.21 Some of the indicators of dementia, such as a
reduction in activities of daily living, decreased attention or ability to plan, are absent in people with MCI.20
Mild cognitive impairment is a heterogeneous state, with possible trajectories including AD, other
dementias, and even reversion to normal cognitive functioning.12 It is also worth noting that the authors of
a meta-analysis22 of 41 inception cohort studies reported that the annual conversion rate from defined MCI
to dementia was approximately 5–10%. The overall conversion rate from MCI to AD has been estimated to
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be between 6% and 25% of cases per year.23 However, these rates vary by subtype of disease. The variation
in the conversion rates could be explained by the differing disease processes13,24 and the heterogeneity
which comes from different populations being studied.25 In epidemiological samples, MCI has often been
classified by applying a psychometric cut-off point to a proportion of cases without in-depth clinical
examination, and a large proportion of these cases subsequently revert to normality.25 In contrast, cases of
MCI diagnosed in secondary care services, following detailed and comprehensive examination and
investigations by a specialist, reveal fewer cases reverting to normality and much higher rates of progression.
Therefore, the concept of MCI depends on how thoroughly the pre-diagnostic assessment is performed.
Mild cognitive impairment is subtyped in terms of the type and number of cognitive domains affected.16
The classification of MCI is described in Table 1.
Different types of MCI have now been proposed, including ‘amnestic form of MCI’, when memory is
affected, and non-amnestic form of MCI, when impairment is in a non-memory domain.16 MCI is also
classified as single-domain or multiple-domain according to the number of cognitive domains with
objectively verified impairment.26
Early dementia
Early dementia is differentiated from MCI by the level of cognitive decline and changes in mood and
behaviour. The common changes experienced by people with dementia can be understood in three stages:
early, middle and late dementia (Table 2). Individuals diagnosed with early dementia present with multiple
cognitive deficits and their memory loss is sufficient to impact on everyday social and occupational
functioning. In the later stages, there is a noticeable deterioration in perception, comprehension and
language. This is also often accompanied by an impaired ability to recognise objects (agnosia) and an
inability to think abstractly and plan, initiate, sequence, monitor and stop complex behaviour.28,29
There are a number of conditions that result in dementia. The three most common reasons are AD
vascular conditions (e.g. multiple cortical/subcortical infarcts), frontotemporal atrophy and Lewy body
disease. Some rare causes of dementia include inherited metabolic disorders (e.g. porphyria), infectious
causes, autoimmune causes and neoplasms (e.g. meningioma).30,31 Irrespective of the primary cause, the
outlook for people with most types of dementia is usually poor. Irreversible or untreated dementia usually
continues to worsen over time until the person’s death.32,33
There are subtle neuropsychological differences in patterns of cognitive deficit in different types of
dementia but, as far as we are aware, there are no dedicated automated tests to specifically diagnose
different types of dementia, such as vascular dementia, alcohol-related dementia or Lewy body dementia.
Furthermore, this is complicated by the fact that authors of studies often use terms inconsistently and
erroneously when describing dementia.
TABLE 1 Mild cognitive impairment subtypes by aetiology, presentation and long-term outcomes
Variable Amnestic Non-amnestic
Aetiology Neurodegenerative disease Vascular damage
Apolipoprotein E Cerebrovascular disease
Presentation Memory impairment present Impairment in non-memory domains
Long-term outcomes Alzheimer’s dementia (AD) Non-Alzheimer dementias: vascular dementia,
Lewy body dementia, frontotemporal
dementia
Source: adapted from Roberts and Knopman.16
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Epidemiology
Obtaining accurate incidence and prevalence figures for MCI is difficult, as people with memory decline
may go undiagnosed. Prevalence and incidence estimates can also vary significantly depending on the
definitions that are used. The variance in these estimates then poses a challenge to the understanding of
the social burden of this disease. For example, the authors of a study utilising data from the Medical
Research Council Cognitive Function and Ageing Study of people aged ≥ 65 years29 estimated the
prevalence of MCI to range from 2.5% to 41.0% in the UK. In addition, the rates of progression from MCI
to dementia varied from 3.7% to 30.0%.29
The most common form of dementia in the UK is AD.34 There are an estimated 163,000 new cases of
dementia identified each year in England and Wales. The risk of being diagnosed with dementia rises with
increasing age; however, a significant portion of people who are diagnosed with dementia are younger
than 65 years.35 The incidence of dementia ranges from 6.7 per 1000 person-years at age 65–69 years to
68.5 per 1000 person-years at age ≥ 85 years. Prevalence increases with age; it is estimated to be 3% by
70 years and then to double every 5.1 years thereafter.36 A report published by the Alzheimer’s Society
predicts that there will be 1 million people living with dementia in the UK by 2025.35
Current diagnostic practice
The 2006 guidelines from the National Institute for Health and Care Excellence (NICE)8 place emphasis on
the early diagnosis of people with dementia to allow for effective management and planning with patients
and carers. The projected increase35 in the prevalence of dementia by the Alzheimer’s Society highlights
the importance of equitable and easy access to diagnosis in the UK patient population.
TABLE 2 Stages of dementia in AD
Stages of dementia Common changes experienced by people with dementia
Early stage l Become forgetful, especially regarding things that just happened
l May have some difficulty with communication
l Become lost in familiar places
l Lose track of the time, including time of day, month, year, season
l Have difficulty making decisions and handling personal finances
l Have difficulty carrying out complex household tasks
l Mood and behaviour
Middle stage l Become very forgetful, especially of recent events and people’s names
l Have difficulty comprehending time, date, place and events
l May become lost at home as well as in the community
l Have increasing difficulty with communication (speech and comprehension)
l Need help with personal care (i.e. toileting, washing, dressing)
l Unable to successfully prepare food, cook, clean or shop
l Unable to live alone safely without considerable support
l Behaviour changes may include wandering, repeated questioning, hallucinations
l May display inappropriate behaviour in the home or in the community
Late stage l Usually unaware of time and place
l Have difficulty understanding what is happening around them
l Unable to recognise relatives, friends and familiar objects
l Unable to eat without assistance, may have difficulty in swallowing
l Increasing need for assisted self-care (bathing and toileting)
l May have bladder and bowel incontinence
l Change in mobility, may be unable to walk or be confined to a wheelchair or bed
l Behaviour changes, including aggression towards carer, non-verbal
l Unable to find his or her way around in the home
Reprinted from World Health Organization, Dementia: A Public Health Priority, © 2012, URL: www.who.int/iris/handle/
10665/75263#sthash.yy7M37Ka.dpuf (accessed 21 July 2015).27
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A schema of the pathway for assessing cognitive impairment in the UK is presented in Figure 1. The first point
of contact with health-care services for a person with suspected cognitive impairment is with a health-care
professional in primary care or in an acute hospital setting. In primary care, the general practitioner (GP)
usually takes a brief history, conducts a physical examination and conducts a short test of cognitive function to
establish a differential diagnosis for cognitive impairment. The NICE guidelines8 recommend the use of the
MMSE when aiming to diagnose people with dementia. It is possible to offer a diagnosis of dementia at this
point if it is in an established state.37 However, MMSE is insensitive to early-stage dementia38 and does not
effectively map the transition from MCI to early dementia.39 The NICE guidelines8 also recommend a number
of pen-and-paper-based tools as suitable tests for screening people for cognitive impairment. Some of these
tests, along others with others used in clinical practice, are further outlined in Table 3.
After this initial screening, the GP refers patients with suspected MCI or early dementia to a memory
assessment service, which is usually based in secondary care and can involve the examination of older
adults by community mental health teams. Memory assessment service teams play an important role in
clarifying the diagnosis (MCI or dementia, subtype and severity of dementia), identifying which patients
with MCI are at greatest risk of developing dementia and determining who are most in need of follow-up.
Diagnoses are clarified by taking a detailed clinical history from the patient and a family member or carer,
interpreting scan results (if needed) and interpreting the findings from cognitive function pen-and-paper
diagnostic tests.44
In an acute hospital setting, patients can be ‘incidentally’ discovered to be living with cognitive impairment
through routine testing for another medical condition, and/or patients may present with acute confusion
secondary to a medical problem.44 There are many different pen-and-paper tests used to aid diagnosis for
MCI and early dementia available for use in a secondary setting; three of the tests most commonly used in
the NHS are described in Table 4.
Primary
care
Acute
hospital 
setting
Diagnosis of
subtype
Memory
assessment
services
Diagnosis of
subtype
GP investigation of
suspected cognitive
impairment
Hospital-based
assessment of
suspected cognitive
impairment
FIGURE 1 Adapted pathway for assessing cognitive impairment.
TABLE 3 Screening tests for cognitive impairment
Test Administration time (minutes) Sensitivity (%) Specificity (%)
GPCOG8 5 82–8540 82–8540
6CIT8 3–4 78.5–8341 77–10041
Mini-Cog assessment instrument42 2–4 76–9940 89–9640
AMT8 2–4 Not validated in a
primary care setting
Not validated in a
primary care setting
Memory Impairment Screen43 4 74–8640 96–9740
6CIT, Six-Item Cognitive Impairment Test; AMT, Abbreviated Mental Test; GPCOG, General Practitioner Assessment
of Cognition.
Source: NICE guidelines8 and clinical advice.
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Reference standard
A reference standard can be described as being the best available method for identifying patients who
have the target condition.50 The reference standard for this research is the clinical diagnosis of MCI and
early dementia. It is recognised that clinical diagnosis itself has a degree of variability, but this is not unique
to dementia studies and does not invalidate the basic diagnostic test accuracy approach. Any recognised
diagnostic criteria (e.g. International Classification of Diseases, Tenth Edition;2 Diagnostic and Statistical
Manual of Mental Disorders-Fourth Edition51 or -Fifth Edition52) can be used.53 Dementia diagnosis may
specify a pathological subtype. Clinicians may use imaging, biomarkers or other data to aid diagnosis, for
example the Clinical Dementia Rating54 which is a gold-standard research criterion against which most
rating scales have been compared.55 However, in this report, diagnoses based only on these tests, without
corresponding clinical assessment, were not included. It is recognised that different iterations of diagnostic
criteria may not be directly comparable and that diagnosis may vary with the degree or manner in which
the criteria have been operationalised (e.g. individual clinician vs. algorithm vs. consensus determination).
Index test
For the purpose of this report, the index test is any automated computerised assessment of cognitive
impairment, which can either be self-administered or interviewer administered. In self-administered tests,
patients may require help with accessing the necessary computer programs, login identification and simple
start-up explanation. It is important to ensure that the patient can see and/or hear the instructions and
test stimuli.
There are several automated tests available to help identify patients with MCI and early dementia. An
accurate automated cognitive assessment tool would be clinically valuable if it were shown to work as well
as clinician-delivered tests. However, there is limited clinical evidence to demonstrate their equivalence or
superiority over standard practice.
The authors of a UK-based review56 investigated the use of several available computerised automated tests
and assessed their sensitivity and specificity for detection of MCI compared with two well-validated pen-
and-paper tests: the Hopkins Verbal Learning Test and the MMSE.56 The authors of the review concluded
that the Hopkins Verbal Learning Test had better sensitivity for the detection of MCI in older adults than
the computerised tests. They also identified that one automated test, CogState, enabled the identification
of cognitive deficits beyond mild impairments in memory; for example, CogState detected more functional
deficits than the Hopkins Verbal Learning Test or MMSE.56 The authors, however, did not address if these
tests had the potential to facilitate timely diagnosis or if they were effective in monitoring disease
progression. Appendix 1 explains measures for assessing an index test against a reference standard.
Table 5 provides a list of automated computerised tests that were identified during the initial scoping
search that was conducted to inform the development of the protocol for this review.
TABLE 4 Tests used to aid diagnosis of MCI and early dementia
Test Administration time (minutes) Sensitivity (%) Specificity (%)
DemTect45,46 8–10 9245 8645
The Montreal Cognitive Assessment:
A Brief Screening Tool For Mild Cognitive
Impairment46
10 9047 8747
Saint Louis University Mental Status48 7 98–10049 98–10049
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TABLE 5 Sample of current automated computerised cognitive tests
Tool Condition Administration
Duration
(minutes) Domains
ANAM56,57 Cognitively impaired
elderly; AD
Mouse/keyboard
Self-administered
NR Memory, attention, psychomotor
speed, language, reaction time
CAMCI56 MCI Touchscreen computer
Self-administered
20 Attention, memory, executive
function, working memory
CANS-MCI56,57 MCI Touchscreen
Self-administered
30 Memory, executive function,
symbol fluency
CANTAB56,57 Early-stage AD;
Parkinson’s disease
Touchscreen
Self-administered
30 Executive function, memory,
attention, visuospatial function
CNSVS56,57 MCI; mild dementia Keyboard
Self-administered
30 Memory, psychomotor speed,
reaction time, complex attention,
cognitive flexibility
CNTB56 AD Keyboard
Technician administered
NR Language, information processing,
motor speed, attention, spatial,
memory
COGDRAS-D56,57 Dementia; AD;
Huntington’s
disease
Yes/no button Technician
administered
20–25 Attention, memory, reaction time
CogState™56,57 MCI Keyboard
Self-administered
15–20 Working memory, attention,
visuospatial memory
CSI56,57 Dementia Keyboard
Self-administered
25–35 Memory, attention, response
speed, processing speed
CST57 NR Technician assisted 15 Learning, memory, executive
function
MCIS56,57 MCI Technician records
responses via telephone
10 Memory, executive function,
language
MicroCog™56,57 MCI Keyboard/pad
Self-administered
> 60a Reaction time, memory, attention,
mental control, reasoning, spatial
processing
Mindstreams™56,57 MCI; dementia Mouse/pad
Technician administered
45–60 Memory, executive function, visual
and special ability
ANAM, Automated Neuropsychological Assessment Metrics; CAMCI, Computer Assessment of Mild Cognitive Impairment;
CANS-MCI, Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment; CANTAB, Cambridge
Neuropsychological Test Automated Battery; CNSVS, Central Nervous System Vital Signs; CNTB, Computerized
Neuropsychological Test Battery; COGDRAS-D, Cognitive Drug Research Computerized Assessment System for Dementia
Patients; CSI, Cognitive Stability Index; CST, Computerised Self-Test; MCIS, Mild Cognitive Impairment Screen;
NR, not reported.
a Duration of short form is 30 minutes.
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Chapter 3 Methods
The methods used in the review followed the systematic review principles outlined in the Centre forReviews and Dissemination’s58 guidance for undertaking reviews in health care, the NICE Diagnostic
Assessment Programme Manual59 and publications from the Cochrane Collaboration Diagnostic Test
Accuracy60 Working Group.
Search strategy
The following electronic databases were searched for the period from 2005 to the latest available version
(August 2015).
l MEDLINE (via OvidSP)
¢ MEDLINE In Process & Other Non-Indexed Citations (via OvidSP)
l EMBASE (via OvidSP)
l The Cochrane Library
¢ Central Register of Controlled Trials
¢ Cochrane Database of Systematic Reviews
¢ Database of Abstracts of Reviews of Effects
¢ Health Technology Assessment database
¢ NHS Economic Evaluation Database
l ISI Web of Science
¢ Proceedings (via Index to Scientific and Technical Proceedings)
¢ ISI Web of Science – Science Citation Index Expanded
l PsycINFO.
The search terms for electronic databases comprised a combination of medical subject heading terms and
free-text words. The search had no language restrictions and there were no limits on specific study design.
Animal studies were excluded, as were case reports, comments, editorials and letters. The details of the
search strategies and the number of references retrieved are provided in Appendix 2.
Grey literature
Theses or PhD abstracts were accessed from ProQuest.
Reference lists
Backwards and forwards citation tracking for all relevant studies and reviews for further possible titles
was undertaken.
Hand-searching
Trial and research registers were hand-searched for ongoing studies and reviews, including:
1. ClinicalTrials.gov
2. Register of Controlled Trials and International Standard Randomized Controlled Trial Number Register
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3. World Health Organization International Clinical Trials Registry Platform
4. PROSPERO systematic review register
5. Epistemonikos.
The resulting database of potentially relevant studies was managed in EndNote X7 (Thomson
Reuters, CA, USA). After individual tests were identified, a second search was run to identify individual
test costs.
Study selection
The citations identified were assessed for inclusion through two stages using Covidence systematic
review software (Veritas Health Innovation Ltd, Melbourne, VIC, Australia).61 Two reviewers
independently scanned all of the titles and abstracts and identified the potentially relevant articles
to be retrieved. Full-text copies of the selected studies were subsequently obtained and assessed
independently by two reviewers. Disagreements were resolved by consensus or in discussions with a
third reviewer.
The eligibility criteria are listed in Table 6 for the diagnostic accuracy studies and in Table 7 for the studies
monitoring disease progression.
TABLE 6 Eligibility criteria: diagnostic accuracy
Criteria Included Excluded
Study design Index test and reference tests are evaluated
in the same study population which
are fully paired (all study participants
receive the index test and the reference
standard)
Any case studies, qualitative studies or
studies with sample size of < 10 participants
Patient population Adults (aged > 18 years) with suspected
MCI or early dementia
Patients diagnosed with neurological
damage caused by stroke or head
injury, learning disabilities or brain tumours
Studies that report on both late
and early stages of dementia were included
only if both the populations were reported
separately
Setting Primary care, secondary care, memory
clinics, acute care settings, care homes,
tertiary or community-based setting
Index test Any commercial or non-commercial
computer-based cognitive diagnostic tool
with automated interpretation, addressing
one or more domains of cognitive
impairment
Automated cognitive diagnostic tool in a
language other than English
Outcomes Diagnostic accuracy (e.g. specificity,
sensitivity, likelihood ratios, diagnostic odds
ratio, intrapatient variability)
Studies not reporting on at least one
diagnostic accuracy outcome
Acceptability (any studies recording a
measure of acceptability)
METHODS
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Data extraction
Two reviewers developed, piloted and standardised two sets of data extraction forms. One form was
designed to collect data on diagnostic accuracy and the other was designed to collect data related to
monitoring disease progression. One reviewer extracted details of study design, participants, index and
reference standard tests, outcome data and other relevant data, and a second reviewer checked the data
extraction. Any discrepancies were resolved by consensus or in discussions with a third reviewer.
Assessment of methodological quality
The quality assessment of studies meeting the inclusion criteria was carried out by one reviewer and
independently checked for accuracy by a second reviewer. The methodological quality of the included
studies was assessed using the QUADAS-2 (Quality Assessment Tool for Diagnostic Accuracy Studies)
tool.62 This tool is designed to evaluate the risk of bias and applicability of primary diagnostic accuracy
studies. The results of the quality assessment are presented in summary tables and as a narrative synthesis.
Outcomes
We recorded the following diagnostic accuracy outcome measures of automated computerised tests for
MCI and early dementia:
1. sensitivity and specificity
2. area under the receiver operating characteristic curve (AUC).
TABLE 7 Eligibility criteria: monitoring
Criteria Included Excluded
Study design Index test and reference tests are evaluated
in the same study population which are
fully paired (all study participants receive
the index test and the reference standard)
Any case studies, qualitative studies or
studies with sample size of < 10 participants
Patient population Adults (aged > 18 years) with diagnosed
MCI and early dementia
Patients diagnosed with neurological
damage caused by stroke or head injury,
learning disabilities or brain tumours
Studies that report on both late and early
stages of dementia were included only if
both the populations were reported
separately
Setting Primary care, secondary care, memory
clinics, acute care settings, care homes,
tertiary or community-based setting
Index test Any commercial or non-commercial
computer-based cognitive monitoring tool
with automated interpretation, addressing
one or more domains of cognitive
impairment used for monitoring disease
progression and treatment
Automated cognitive diagnostic tool in a
language other than English
Outcomes Monitoring accuracy (e.g. specificity,
sensitivity, likelihood ratios, diagnostic odds
ratio, intrapatient variability)
Studies not reporting on at least one
monitoring outcome
Acceptability (any studies recording a
measure of acceptability)
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Method of analysis/synthesis
Statistical analysis and data synthesis
Individual study results
The results of the individual diagnostic studies were tabulated and sensitivity, specificity, predictive values,
likelihood ratios (LRs) and diagnostic odds ratios were calculated for the index test for each study where
true-positive (TP), true-negative (TN), false-positive (FP) and false-negative (FN) data were available (see
Appendix 1). These data were required to establish the actual sensitivity and specificity of a test for a given
cut-off value. From this point onwards, TP, TN, FP and FN data will be referred to as 2 × 2 data. These
terms are explained in detail in Appendix 1.
The authors of all of the studies included in this review were individually approached with a request for
specific 2 × 2 data whether or not they were available in the published report. Out of 15 authors, only two
responded and were able to provide these data.
Meta-analysis
It was not possible to perform a meta-analysis owing to non-comparable data; for example, study designs
varied, the primary outcome measure cut-off points were heterogeneous, the likelihood of bias differed
across the studies and the summary statistics were often inconsistently reported. The results of the
included studies have been synthesised narratively and in tables. The possible effects of study quality
(based on the assessment of risk of bias) on the 2 × 2 data and review findings have been considered.
Patient and public involvement
The review team was guided during the review by an Advisory Group comprising clinicians and service users.
Building trusted contacts with service users led us to believe that the most effective way to obtain
engagement with service users was through frontline agencies, for example the Alzheimer’s Society and
Dementia UK. We sent out a call for participation through these frontline groups to identify people interested
in giving feedback on the results of the review and on the final report. We took guidance from these
agencies when we planned and facilitated our meetings and consulted the guidance available from INVOLVE
on the principles of involving the public in research from the National Institute for Health Research.63
METHODS
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Chapter 4 Results
Initial searches and application of inclusion criteria
The results of the searches and study selection are presented in Figure 2. The initial electronic search was
conducted in August 2015 and 13,352 records were retrieved. An additional 5444 records were identified
through ProQuest, hand-searching and citation tracking. After deduplication, 13,542 titles and abstracts
were screened and 399 articles were shortlisted for full-text assessment. Four trials were identified during
hand-searching:64–67 two are still recruiting participants,64,67 one has been completed but the results have
not been published66 and the status of one trial65 is unknown. The authors of these studies were
approached by e-mail and telephone for results, but no responses were received. These studies are
tabulated in Table 21 in Appendix 2.
The reasons for excluding studies are tabulated in Appendix 3.
All of the tests (computerised and pen-and-paper) identified during screening are listed in Appendix 4.
Records after duplicates removed
(n = 13,542)
Records screened on title and abstract
(n = 13,542)
Records excluded
(n = 13,143)
Full-text articles assessed for eligibility
(n = 399)
Records included in diagnostic 
accuracy review
(n = 16)
Full-text articles excluded
(n = 383)
• Paper-based test, n = 116
• Wrong study design, n = 59
• Wrong indication – other, n = 55
• Not an evaluation of the 
   automated test, n = 31
• Wrong patient population, n = 32
• Systematic review, n = 23
• Literature review, n = 20
• Wrong intervention, n = 16
• Wrong outcomes, n = 9
• Wrong outcomes; continuous 
   data, n = 6
• Automated test not in 
   English, n = 9
• Timeline, n = 4
• Duplicate, n = 3
Records identified through
database searching
(n = 13,352)
Additional records identified 
through ProQuest, hand-searching
and citation tracking
(n = 5444)
FIGURE 2 The PRISMA flow diagram.
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Included studies
In total, 16 studies68–72,74–81,83,85,86 were included in the diagnostic accuracy review.
No studies met the review inclusion criteria for monitoring progression in MCI or early dementia and,
therefore, there is no further mention of monitoring disease progression in the results section.
The details of the 16 included studies68–72,74–81,83,85,86 are summarised in Tables 8–10. Five studies reported
results for more than two groups of participants: three included healthy controls, MCI and early
dementia,71,76,86 and two included healthy controls, early dementia and early dementia/MCI combined.70,74
In total, 10 studies68,69,71,72,75,76,78,79,85,86 evaluated the use of automated computerised tests to detect MCI
alone, seven studies70,71,74,76,80,81,86 reported results for early dementia, three studies70,74,77 reported results
for combined MCI/early dementia and one study83 reported results for human immunodeficiency virus
(HIV)-associated neurocognitive disorder (HAND).
The information in Table 8 shows that the index tests assessed in the included studies varied. However, the
references tests used in the studies were generally consistent across studies for patients with MCI and for
patients with early dementia.
TABLE 8 Included studies: summary
Study and year Condition
Irrelevant study
groups Index test Reference test
Company
funding/
financial
interest
Ahmed et al.68
2012
MCI NA CANS-MCI Clinical diagnosis
using Petersen’s
criteria
No
de Jager et al.69
2009
MCI NA CogState Clinical diagnosis
using battery of
neurocognitive tests
No
Doniger et al.70
2005
MCI
MCI/mild
dementia
NA Mindstreams Clinical diagnosis
using Petersen’s
criteria20 for MCI
and DSM-IV51 for
dementia
Yes
Not-for-profit
Dwolatzky et al.71
2003
MCI
Mild AD
No relevant results
reported for mild
AD group
Mindstreams Clinical diagnosis
using Petersen’s
criteria20 for MCI and
DSM-IV51 for mild AD
Yes
Juncos-Rabadán
et al.72 2014
aMCI NA CANTAB Clinical diagnosis
using neurocognitive
tests and Albert
criteria73 and Peterson
criteria20 for aMCI
No
Junkkila et al.74
2012
aMCI/mild/
probable
dementia
Mild/probable
dementia
NA CANTAB-PAL Clinical diagnosis
using Petersen’s
criteria20 and
neurocognitive tests
No
Kingsbury et al.75
2010
MCI Depressed CogniScreen Clinical diagnosis
using Petersen’s
criteria20
NR
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TABLE 8 Included studies: summary (continued )
Study and year Condition
Irrelevant study
groups Index test Reference test
Company
funding/
financial
interest
Kluger et al.76
2009
MCI
Early dementia
Other dementias No name Diagnosed by a
consensus of at least
two clinicians
No
Lichtenberg
et al.77 2006
MCI/early
dementia
CST Clinical diagnosis
using Petersen’s
criteria;20 clinical
diagnosis of dementia
using DSM-V52
NR
Maruff et al.79
2013
MCI Mild to moderate
AD
CBB Clinical diagnosis
using Peterson
criteria20
Yes
Mundt et al.80
2001
Dementia Moderate stage of
dementia
Computer-
automated
telephone
screening
Clinical diagnosis
using CDR score
No
O’Connell et al.81
2004
Probable AD NA CANTAB-PAL Clinical diagnosis
using NINCDS-
ADRDA82 criteria
NR
Rosenthal et al.83
2013
HAND HIV-negative
people; HIV-positive
people with
asymptomatic
neurocognitive
impairment
and minor
neurocognitive
disorder
CAMCI
modified for use
in HIV-positive
population
HAND category using
the Frascati criteria84
Yes
Saxton et al.85
2009
MCI NA CAMCI Clinical diagnosis
by consensus
using battery of
neurocognitive tests
and functional and
medical information
Yes
Tierney et al.78
2014
MCI NA CAMCI Clinical diagnosis
using battery of
neurocognitive tests
No
Vacante et al.86
2013
MCI
Early dementia
NA TPT Clinical diagnosis
using Petersen’s
criteria20
No
aMCI, amnestic mild cognitive impairment; CAMCI, Computer Assessment of Mild Cognitive Impairment; CANS-MCI,
Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment; CANTAB, Cambridge
Neuropsychological Test Automated Battery; CANTAB-PAL, Cambridge Neuropsychological Test Automated Battery Paired
Associated Learning; CBB, CogState Brief Battery; CDR, Clinical Dementia Rating Scale; CST, Computerised Self-Test;
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition; DSM-V, Diagnostic and Statistical Manual
of Mental Disorders-Fifth Edition; HAND, HIV-associated neurocognitive disorder; HIV, human immunodeficiency virus;
NA, not applicable; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association; NR, not reported; TPT, The Placing Test.
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TABLE 9 Index test details
Study and year Test name
Cognitive
domains tested
Details of test
platform used
Time
(minutes)
Method of
administration
Ahmed et al.68
2012
CANS-MCI Memory
Language
Visuospatial
Executive function
Desktop computer,
a touchscreen system
with both oral (loud
speakers) and
on-screen instructions
30 Self-administered
Researcher in room
de Jager et al.69
2009
CogState Memory
Executive function
Attention
Processing speed
Internet ≈20 Self-administered
Practice session with
a psychologist
Doniger et al.70
2005
Mindstreams
(abridged)
Memory
Executive function
Visuospatial
Motor skills
Computer and mouse 30 Self-administered
Practice session
Dwolatzky
et al.71 2003
Mindstreams Memory
Executive function
Visuospatial
Verbal
Attention
Information
processing
Motor skills
Designed for use with
the elderly. Mouse
with the number pad
on the keyboard
(similar to the
telephone keypad)
45 Self-administered
Practice session with
feedback prior to
testing
Research assistant
Juncos-Rabadán
et al.72 2014
CANTAB-R
(DMS, PAL
and PRM)
Memory Touchscreen computer NR Self-administered
Researcher present
Junkkila et al.74
2012
CANTAB-PAL Memory Touchscreen computer NR Self-administered
Kingsbury et al.75
2010
CogniScreen Memory Laptop, headset with
microphone
20–40 Self-administered
Experimenter in
room
Kluger et al.76
2009
Computerised
test (no name)
Memory
Praxis
Naming
Executive function
Laptop 12–15 Self-administered
Screening test for
computer
competency
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TABLE 9 Index test details (continued )
Study and year Test name
Cognitive
domains tested
Details of test
platform used
Time
(minutes)
Method of
administration
Lichtenberg
et al.77 2006
CST Learning
Memory
Executive function
Internet based,
interface with both
written and oral
instructions
15 Self-administered
Keyboard proficiency
test
Administered by
graduate psychology
student
Maruff et al.79
2013
CBB Memory Desktop computer,
yes/no button attached
through USB port
10 Self-administered
Verbal instructions
by supervisor
Practice session
Mundt et al.80
2001
Computer-
automated
telephone
screening
Memory
Spatial (auditory)
Executive function
Orientation
Language
Standard touch-tone
telephones
11–15 Self-administered
Researcher provided
assistance in dialling
the number
O’Connell et al.81
2004
CANTAB-PAL Memory Touchscreen computer 10 NR
Rosenthal et al.83
2013
CAMCI
Modified
Memory
Attention
Executive function
Processing speed
Tablet with stylus 25 Self-administered
Saxton et al.85
2009
CAMCI Memory
Attention
Executive function
Processing speed
Desktop computer ≈20 Self-administered
Tierney et al.78
2014
CAMCI Memory
Attention
Executive function
Processing speed
Tablet computer 30 Self-administered
some required
researcher assistance
Vacante et al.86
2013
TPT Memory Computer 20 Self-administered
Including practice
pages
CAMCI, Computer Assessment of Mild Cognitive Impairment; CANS-MCI, Computer-Administered Neuropsychological
Screen for Mild Cognitive Impairment; CANTAB, Cambridge Neuropsychological Test Automated Battery; CANTAB-PAL,
Cambridge Neuropsychological Test Automated Battery Paired Associated Learning; CBB, CogState Brief Battery; CST,
Computerised Self-Test; DMS, Delayed Matching to Sample; NR, not reported; PAL, Paired Associated Learning; PRM,
Pattern Recognition Memory; TPT, The Placing Test.
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Study quality assessment
A summary of the quality assessment conducted is presented in Figures 3 and 4.
We used the modified form of QUADAS-2,62 which is recommended by the Cochrane Diagnostic Test
Accuracy Reviews Guidelines,87 to assess the quality of the included studies. Concerns regarding the risk of
bias and applicability have been presented as a summary and as percentages in Figures 3 and 4, respectively.
The risk-of-bias criterion for patient selection was high for seven studies,71,72,74–76,81,83 unclear for one study86
and low for eight studies.68–70,77–80,85 The studies were judged to be at high risk for this criterion because a
case–control study design was used.
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Regarding the index test criteria for risk of bias, seven studies70,71,74,76,78,83,85 were judged to be at unclear
risk. In these studies, the threshold values for the index tests were not pre-specified. However, for all of
these studies, except Dwolatzky et al.,71 it was clear that the index test results had been interpreted
without knowledge of the results of the reference standard.
We gave a judgement of high concern regarding applicability of the index test for all of the
studies68–72,74–81,83,85,86 because the interpretation of the index test was different from the review question,
as it is not possible to diagnose MCI and early dementia using automated computerised tests in isolation;
specialist expertise is necessary to establish a diagnosis.
The reference standard domain for the risk of bias was unclear in eight studies,68,69,72,75,79–81,86 as it was
not possible to ascertain whether or not reference standard results were interpreted without knowledge
of the results of the index tests. However, the reference standard used in each of the studies was likely
to correctly classify the target condition. All studies but one76 were judged to have low concern for
applicability regarding the reference standard. The one study76 used a consensus of two clinicians’ opinions
as the reference standard.
In the flow and timing domain for the risk of bias, a judgement of unclear risk of bias was given to two
studies72,83 as a result of there being no details of timing or attrition described in the published papers. Not
all of the studies (n = 11)68–71,74,76,77,79,80,85,86 reported whether or not there had been an appropriate interval
between the index test and the reference standard. However, 14 studies68–71,74–81,85,86 were assessed as
being at low risk owing to all patients having received the same reference standard and all patients being
included in the analysis.
Although only one study77 was judged to be at low risk of bias across the four domains, the studies were
considered to be of good quality. Patient selection issues were the most likely to introduce bias.
The only concern for applicability was the one previously mentioned, that is the interpretation of the index
test was different from the review question as it is not possible to diagnose MCI and early dementia using
automated computerised tests in isolation.
Index test details
The time required to self-administer the different index tests ranged from 10 minutes79,81 to 45 minutes.71
A range of cognitive domains was tested across the different tests, memory and executive function being
the most common. Even though all of the tests were self-administered, a practice session was offered to
participants in five studies69–71,79,86 to make sure that patients were familiar with the software and platform
for the index test. Nine studies68,69,71,72,75,77–80 reported that support staff were present in the room to
address any questions from participants about the software or platform.
0% 25%
Applicability concerns
75% 100%0%
Patient selection
Index test
Reference standard
Flow and timing
25% 50% 50%
Risk of bias
75% 100%
High
Unclear
Low
FIGURE 4 Risk of bias and applicability concerns graph: presented as percentages.
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Study and participant characteristics
The characteristics of the included studies are presented in Table 10. A total of 2832 people were included
in the studies, with the number of people in each study ranging from 5085 to 766.81
Two studies were multicentred71,85 and one study71 was carried out internationally, in Canada and Israel.
The earliest study was published in 200180 and two were recently conducted in 2014.72,78 The study
participants were generally similar across the studies (owing to relatively similar study inclusion and
exclusion criteria), although four studies69,80,81,86 did not report their exclusion criteria.
The participants were mainly recruited through primary care68,72,79,85,86 or from a memory clinic.71,75,76,81
Six studies were based in the USA,70,76,77,80,83,85 three were based in the UK,68,69,86 two were based in
Australia,75,79 one was based in Ireland,81 one was based in Canada and Israel,71 one was based in Canada,78
one was based in Spain72 and one was based in Finland.74 Participants in 13 studies68,70–72,74,75,77–80,83,85,86 had
874 to 2280 years of education; for the other three studies, data describing the education of the participants
were not reported.69,76,81 Only five studies70,72,77,83,85 reported data on ethnicity. There is a lack of demographic
data in two studies69,76 for participants who were tested for MCI. Fifteen studies reported on cognitive
impairment without comorbidities.68–72,74–81,85,86 One of the included studies reported on cognitive impairment
with a comorbidity (i.e. HIV).83
Results from studies on cognitive impairment without
comorbidities
The diagnostic accuracy of 11 automated computerised tests for the detection of MCI and/or early
dementia without comorbidities was evaluated in 15 studies.68–72,74–81,85,86 One study76 evaluated a test
which did not have a name. Three studies72,74,81 reported on multiple or singular domains of the Cambridge
Neuropsychological Test Automated Battery (CANTAB). The pooling of data from these 15 included studies
was considered inappropriate as there were few studies evaluating the same index test in the same
population, and it was possible to extract 2 × 2 data from only five72,74,80,81,85 of the 15 studies.
Studies reporting on diagnostic accuracy outcomes with 2 × 2 table
There were five studies72,74,80,81,85 that reported diagnostic accuracy outcomes in a 2 × 2 table. Two
studies72,85 reported the diagnostic accuracy outcomes for MCI, three studies74,80,81 reported outcomes for
early dementia and one study74 reported combined outcomes for both MCI/early dementia. When possible,
the positive predictive value (PPV), negative predictive value (NPV), positive LR (LR+) and negative LR (LR–)
were calculated using 2 × 2 data.
Mild cognitive impairment
The diagnostic accuracy outcomes for the two studies72,85 reporting 2 × 2 data for MCI are presented in
Table 11. The study by Juncos-Rabadán et al.72 evaluated three different visual episodic memory tests
included in the CANTAB; these memory tests were Pattern Recognition Memory, Delayed Matching to
Sample and Paired Associated Learning. The overall sensitivity and specificity for the three visual episodic
memory tests was moderate, at 79.7% and 76.3%, respectively. The AUC ranged from 0.623 to 0.747,
which shows poor ability to discriminate between the MCI group and the non-MCI group. This test had a
high overall PPV of 71.4%; this means that 71.4% of the people who tested positive for MCI with the
reference standard actually had MCI. Similarly, the overall NPV for this test was 83.3%, meaning that
83.3% of people who tested negative for MCI on the reference standard did not have MCI. This test had a
low overall LR+ of 3.4, which shows a low likelihood of the test to establish the presence of disease. It also
had a low overall LR– of 0.3, which shows a low likelihood of the test to establish the absence of disease.
The study by Saxton et al.85 evaluated the Computer Assessment of Mild Cognitive Impairment (CAMCI) and
reported good sensitivity (86%) and exceptional specificity (94%), with an exceptional AUC of 0.91.
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Early dementia
The diagnostic accuracy outcomes for the three studies74,80,81 reporting 2 × 2 data for patients with early
dementia are presented in Table 12. The Cambridge Neuropsychological Test Automated Battery Paired
Associated Learning (CANTAB-PAL) was evaluated in two of the studies.74,81 The authors of one study74
reported high sensitivity (81.8%) and specificity (97.2%) and an AUC of exceptional discrimination (0.914)
for early dementia. It also had a PPV of 94.7% and a NPV of 89.7%.
The study by O’Connell et al.81 reported poor sensitivity (67.6%) and high specificity (100%) and an
AUC of moderate discrimination between the early dementia group and non-early dementia group (0.78).
The authors also reported a PPV of 100.0% and a NPV of 59.3%. This test also had a low LR– of 0.324
for early dementia.
Mundt et al.80 assessed the Computer Automated Telephone System and reported moderate sensitivity
(79.17%) and high specificity (83.8%) for this test. The authors reported an AUC of 0.819, which shows
good discrimination. The test also had a PPV of 76.0%, a NPV of 86.1%, a low LR+ of 4.88 and a low
LR– of 0.249 for dementia.
Mild cognitive impairment/early dementia
The diagnostic accuracy outcomes for the one study74 reporting 2 × 2 data for MCI/early dementia are
presented in Table 13. This study evaluated CANTAB-PAL. The authors reported high sensitivity (96.9%)
and high specificity (80.8%), with an AUC of good discrimination (0.897) between the MCI/early dementia
group and non-MCI/early dementia group. The test had a PPV of 86.1% and a NPV of 95.5%; it also had
a low LR+ of 5.04 and low LR– of 0.04 for MCI/early dementia.
Studies reporting on diagnostic accuracy outcomes without 2 × 2 table
The authors of 10 studies68–71,75–79,86 reported diagnostic accuracy outcomes for nine different index tests
without using 2 × 2 data. Instead, the authors of the studies calculated optimal sensitivity and specificity
values using receiver operating characteristic curve analysis. The authors of seven studies reported the
optimal sensitivity and specificity.68,69,75,77–79,86 There were seven studies that reported AUC values.68–71,75,76,79
Two studies reported PPV and NPV,68,77 and no study reported LR+ and LR– results. The outcome measures
presented in these studies are tabulated in Tables 14–16.
Mild cognitive impairment
The diagnostic accuracy outcomes reported in eight studies68,69,71,75,76,78,79,86 for MCI are presented in
Table 14. Ahmed et al.68 evaluated Computer-Administered Neuropsychological Screen for Mild Cognitive
Impairment and reported high sensitivity (89.0%) and moderate specificity (73.0%) with an AUC of 0.867,
which shows a good ability to discriminate between the MCI group and the non-MCI group.
Tierney et al.78 evaluated the CAMCI test and reported a high sensitivity (80.0%) and a moderate
specificity (74.0%); the authors did not report AUC PPV, NPV, LR+ or LR– values.
Maruff et al.79 evaluated the CogState Brief Battery. The CogState Brief Battery has two composite scores
for four tasks: psychomotor function, attention function, learning memory and working memory. The
psychomotor/attention function had poor discrimination, as its AUC was 0.67. It also had poor sensitivity
(41.1%) but high specificity (85.7%). The AUC for the learning/working memory was 0.91, which shows
exceptional ability to discriminate between the MCI group and the non-MCI group. It also had high sensitivity
(80.4%) and high specificity (84.7%). The overall sensitivity, specificity and AUC were not reported.
Early dementia
The diagnostic accuracy outcomes for early dementia were assessed in four studies70,71,76,86 and are
presented in Table 15.
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Dwolatzky et al.71 did not report any results for early dementia patients, despite relevant data for this
group having been collected during the study. Doniger et al.70 evaluated an abridged version of
Mindstreams and reported an overall AUC of 0.886, which showed a good ability to discriminate between
the early dementia group and the non-early dementia group.
Kluger et al.76 evaluated an automated computerised test, which did not have a specific name. This
automated test examined the domains of memory, praxis, temporal, orientation, naming and crossed
response inhibition. The authors reported an AUC of 0.97, which shows exceptional ability to discriminate
between patients with early dementia and healthy control subjects.
Mild cognitive impairment/and early dementia
The diagnostic accuracy outcomes in two studies70,77 for MCI/early dementia are presented in Table 16.
Doniger et al.70 reported an overall AUC of 0.823, which showed a good ability to discriminate between
the cognitively healthy group and the cognitive unhealthy group. AUC values for individual test results
ranged from 0.671 to 0.773.
Lichtenberg et al.77 reported values for sensitivity and specificity (80.0% and 87.0%, respectively),
PPV (88.0%) and NPV (79.0%).
Results from studies on cognitive impairment with
comorbidities
The diagnostic accuracy of one automated computerised test was evaluated in one study83 that included
people with cognitive impairment with comorbidities. This study examined HAND and used the automated
test CAMCI. CAMCI assessed multiple domains with different tasks, which included simple reaction time,
recurring picture, go/no go rule 1, go/no go rule 2, word recall, digit span forward, digit span reverse,
shopping trip directions task, shopping list task, errand – bank, errand – post office, completion of the
shopping list task and incidental recall task. The study set out to examine a range of diagnostic accuracy
outcomes, but did not report the values for all of them.
The study authors state that the AUC analyses indicate that the digit span, forward digit span size and
functional driving task differentiated between HIV-positive individuals with and without HAND.83 However,
the results presented show a low to moderate sensitivity but poor specificity. The authors of the study
presented values for several, but not all, tests. It was reported that, in the forward digit span, a raw score
cut-off point of ≥ 6 gives a sensitivity of 63.0% and a specificity of 19.0% and a forward span size raw
score cut-off point of ≥ 5 gave a sensitivity of 80.0% and a specificity of 9.0%. The study also reported
that the raw score on the shopping trip directions task of ≥ 13 gave a sensitivity of 75.0% and a specificity
of 18.0%.83
Patient and public involvement
Data from the included studies describing the index test details, characteristics of study participants and
diagnostic accuracy outcomes were presented and discussed with a service user. The structure of this
meeting is described in Appendix 5. As some of the index tests showed high sensitivity and specificity
when used to examine one or two cognitive domains, the service user thought that all of the index text
domains ought to have been explored by the authors of the studies to enable a comprehensive overview
of any cognitive impairment identified. In addition, the service user considered that more information on
key domains would help clinicians and patients to address the challenges faced by patients with MCI or
early dementia as they carry out their everyday activities. The service user thought that the studies covered
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different populations very well, but raised concerns about the age of the study participants, as none of the
tests evaluated cognitive impairment in people older than 90 years of age. A further concern was that the
level of education of the person being tested might affect his or her performance on the test.
The discussion with the service user was mostly centred around the importance of the index tests being
user-friendly and acceptable to patients. In a conversation about the different kinds of platforms used
for the tests, the service user noted that if a patient had tremors then a desktop computer would be
preferred to a touchscreen test, especially if the touchscreen test was very sensitive to touch.
When discussing the different types of tests available, the service user also highlighted the importance of
ensuring that the test had a clear contrast between colours because it is likely that older people will have
cataracts, colour blindness or other problems with their eyesight.
The service user also stated that some people might become frustrated with tests that lasted longer than
40 minutes, especially people who are not familiar with modern technology and people who are
considered to be very elderly. The service user suggested that a patient’s GP might be the best person to
make a decision about whether or not the patient would be able to complete an automated test and
generate meaningful results, as some people are more comfortable than others when using technology.
Individual test costs
After identifying the individual index tests via searching, a second search was run to identify the total costs
of using these computerised tests and, where possible, to determine the acquisition costs of the tests.
A number of grey literature sources generated some cost data, but it was not clear if these costs were
yearly subscription costs for an organisation that had planned to use the test or if they were one-off costs
for the use of one test by one person.88–91 The authors of the publications did not state whether or not
the costs also included the costs associated with training or administering the test, and the need for a
health-care specialist to score/interpret the test was not discussed.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Chapter 5 Discussion
Summary of main results
We identified 16 studies68–72,74–81,83,85,86 for inclusion in the diagnostic accuracy review of automated
computerised tests to detect MCI or early dementia; only one study83 included patients with comorbidities.
No studies met the review inclusion criteria for monitoring disease progression.
Ten studies68,69,71,72,75,76,78,79,85,86 evaluated the use of automated computerised tests to detect MCI alone,
seven studies70,71,74,76,80,81,86 reported results for early/mild dementia, three studies70,74,77 reported results for
combined MCI/early dementia and one study83 reported results for HAND.
Eleven different index tests were evaluated. The only study which evaluated the diagnostic accuracy of
automated computerised tests for people with cognitive impairment with comorbidities was conducted by
Rosenthal et al.83
Most of the included studies had small sample sizes; 10 studies68,69,71,72,74–77,81,86 had fewer than 150
participants and only two studies79,85 had more than 500 participants. Differences in study design, primary
outcome measure cut-off points, the likelihood of bias, the reporting of summary statistics (e.g. 2 × 2 data)
and disparity in the index tests precluded a meta-analysis of the data reported in the included studies.
Meaningful synthesis of the diagnostic outcomes from the included studies was not possible.
Of the 16 studies,68–72,74–81,83,85,86 only one77 was judged to be at low of risk of bias across the four domains
examined; despite this, the overall quality of the included studies was considered to be good. Patient
selection issues were the most likely to introduce bias. The only concern for applicability was the one
previously mentioned, that is, the interpretation of the index test was different from the review question as
it is not possible to diagnose MCI and early dementia using automated computerised tests in isolation.
Applicability of findings to the review question
Ideally, for diagnostic purposes, an index test with high specificity is preferable, and high sensitivity is
preferred for screening.92 When diagnosing patients with MCI and/or early dementia, an index test with
both high sensitivity and specificity is needed to be able to appreciate a distinctive pattern of cognitive
impairment in MCI and early dementia. This distinctive pattern of cognitive impairment is different from
the cognitive impairment caused by other disease processes (e.g. cognitive impairment as presented in
depression or HIV). The distinctive pattern of cognitive impairment caused by other conditions such as
depression requires the use of elaborate scales such as the Cambridge Cognitive Examination,93–95
the Alzheimer’s Disease Assessment Scale96,97 or the Repeatable Battery for the Assessment of
Neuropsychological Status.98,99 Current pen-and-paper tests screening instruments for MCI cannot do this.
In the case of HIV, however, it is difficult to draw a clearer distinction in the pattern of cognitive
impairment, as no attempt has been made to adapt the diagnostic criteria for HAND to the pattern of
cognitive domains that are affected in HIV.84,100,101 Although it is difficult to find robust data, the dominant
theory is that HAND causes deficits primarily in executive function, psychomotor speed and attention.
Language is not thought to be affected, and neither are learning nor recall, although deficits in the other
domains can present themselves to the patient as communication and memory difficulties in the ‘real-life’
scenario (as opposed to the testing environment).102 This makes it difficult to separate it from or equate it
to MCI or early dementia.
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Most studies were not conducted in samples representative of the usual clinical population in which these
tests might be used (e.g. patients coming to memory clinics with a mix of MCI and dementia of various
aetiologies, some were the ‘worried well’ and others were depressed) but were conducted in convenience
samples of patients with limited diagnoses (mostly MCI and AD). Furthermore, only three studies68,69,86
out of 16 were conducted in the UK.
It is difficult to draw a clear picture of the diagnostic accuracy of the index tests that were assessed in this
review, as there is not enough evidence to support the use of one test over another.
It is not clear from reviewing the included studies if these computerised tests ought to be used in primary
and/or secondary care. In the UK, some GP practices take part in ‘case finding’ for dementia, for example
specifically targeting ‘high-risk’ groups (e.g. older adults, or patients with high vascular risk, learning
disability or Parkinson’s disease), and hospital staff undertake brief cognitive assessments during all acute
admissions for older adults.
The pen-and-paper tests currently used in clinical practice not only help clinicians differentiate between
normal cognition, MCI and dementia,45,46,48 but also assist in staging severity of illness. In contrast,
CANTAB was the only automated test in this review that could stage severity.72,74,81 The time taken to
complete these computerised tests varied between 10 and 45 minutes but was not reported in two
studies.72,74 In contrast, pen-and-paper-based tests typically range from 7 to 10 minutes to complete.45,46,48
Concern for the time it takes to complete the tests was raised by the service user, who pointed out the
possibility of people becoming frustrated with tests that lasted for more than 40 minutes, especially if they
were not familiar with using technology.
The data in the included papers did not describe the time required for training, administration, scoring and
interpreting the test results.
Comparisons with previous research
None of the previously conducted relevant reviews56,57,103 in this area carried out a diagnostic accuracy
review. They were narrative reviews56,57,103 that provided a summary of the battery of tests used and then
rated this evidence on validity and reliability, comprehensiveness, and usability. Our review focused on
automated computerised tests that were self-administered and had a minimum level of involvement from
health-care professionals. In line with our review findings, the authors of the other reviews56,57,103
concluded that there are significant differences in automated computerised tests and hence they must be
judged on a case-by-case basis.57
Strengths and weaknesses of the review
The search strategy for this review was extensive and included multiple databases and grey literature
sources. The majority of studies were identified by terms related to the index test, the terminology for
which is reasonably standardised. To capture the difficult-to-locate studies where the index test is not
referred to in the parts of the electronic record available for search retrieval, we searched the Cochrane
Dementia and Cognitive Improvement Group’s register of diagnostic test accuracy studies. The
methodological rigour of the review process was enhanced by the use of two assessors to perform citation
screening, quality assessment and data extraction/checking. We also contacted all of the primary study
authors and asked them to fill in the actual values of a 2 × 2 table. Out of 15 authors, only two were able
to send in the requested details. We also conducted a patient and public involvement exercise, but were
able to receive feedback on our review findings from only one service user representative.
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We excluded studies in which the automated tests or the studies evaluating the automated test were not
described in English. The utility of this review is limited in part by the heterogeneity of the automated
computerised tests assessed in the included studies. Owing to substantial diversity in the index tests and
the characteristics of the participants, it was not appropriate to pool the data. The poor reporting of the
diagnostic accuracy outcomes by the authors also hampered data extraction, quality assessment and
meaningful synthesis.
We were also unable to identify any studies that reported on any measure of test acceptability. We did not
identify any studies that reported outcomes related to monitoring disease progression.
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Chapter 6 Conclusions
Implications for practice
The overall quality and quantity of information is insufficient to be able to make recommendations on the
clinical use of the computerised tests for diagnosing and monitoring MCI and early dementia progression.
The suitability of these tests also depends on the costs of the test, training, administration and scoring.
Increased effectiveness of a test could offset the costs of the test, equipment and staff training.
The diagnosis of patients with MCI and early dementia is currently based on clinical judgement and
medical history as well as on the results of cognitive tests. However, a ‘definitive’ diagnosis of dementia
can be made only after a post-mortem analysis of the brain. We also note that autopsy studies in dementia
have shown that there is little correlation of these results with the clinical diagnosis made when patients
were alive. Therefore, the reference standard remains a clinical diagnosis based on history and physical and
cognitive examination. For this reason, we would recommend against approaches that use computerised
tests in isolation. Even with pre-specified cut-off values for a particular population, any cognitive testing
measure alone is insufficient to render a diagnostic classification: other relevant clinical information must
be taken into account.
Older people are more likely to have motor limitations (e.g. as a result of strokes, pain or tremor) or
vision and hearing impairments that may render computerised testing impractical. This raises the issue
of whether or not these tests can be truly self-administered and valid. For these patients, automated
computerised tests may not offer benefits over current practice.
Implications for research
Further research is required in order to establish stable cut-off points for each automated computerised
test used to diagnose patients with MCI or early dementia. These cut-off points need to be tested in
specific patient populations, for example in patients of different age groups or education levels and from
different geographical regions.
The prevalence of dementia and alternative diagnoses in the study populations should be clearly reported
and make reference to standardised checklists for diagnostic reviews such as Standards for Reporting
Diagnostic Accuracy104 or Standards for Reporting Diagnostic Accuracy – dementia.105 Investigators might
consider evaluating automated computerised test performance at different cut-off points, across
populations with varying prevalence of MCI and early dementia. Once sufficient studies in the defined
populations are conducted, further reviews and meta-analyses can be carried out.
Future research in this area should also focus on providing more information on the costs of computerised
tests and include time for training, administration and scoring of the different tests, as these are important
factors for their use in routine clinical practice. This type of information is currently lacking in the published
studies describing computerised tests used to diagnose or monitor people with MCI or early dementia.
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Appendix 1 Measures for assessing an index test
against a reference standard
The following section outlines the different methods of assessing diagnostic outcomes. It is adaptedfrom a previous piece of work conducted by the Liverpool Review and Implementation Group (LRiG)
and is reproduced here with permission.106
The classic presentation of the results of a clinical validity study is the so-called 2 × 2 table, as shown in Table 17.
The number entered into cell ‘a’ is the number of patients for whom the new test correctly diagnoses MCI
(as determined by the reference standard, in this case a clinical diagnosis of MCI). For these people, the
new test is positive as is the reference standard; these are TPs.
The number entered into cell ‘b’ is the number of patients for whom the new test is positive (i.e. indicates
the presence of MCI) but who do not, according to the reference standard (clinical diagnosis), have
MCI. The new test has incorrectly diagnosed MCI; these are FPs.
The number entered into cell ‘c’ is the number of patients who are identified through the reference
standard (clinical diagnosis) as having MCI but for whom the new test gave negative results. The new test
has incorrectly labelled the patient as having MCI; these are FNs.
The number in cell ‘d’ is the number of patients who do not, according to the reference standard (clinical
diagnosis), have MCI and who are also shown by the new test to be free from disease; these are TNs.
The numbers displayed in a 2 × 2 table are used to generate other summary measures. These are set out in
Table 18.
In an ideal world, a test would be 100% sensitive and 100% specific. However, in reality there is often a
trade-off between the two, with tests that have high sensitivity having low specificity and vice versa.
TABLE 17 Example of a 2 × 2 table
Test result
Clinical diagnosis (reference standard)
MCI No MCI
New test positive a b
New test negative c d
TABLE 18 Summary measures derived from numbers in a 2 × 2 table
Term Formula Notes
Sensitivity a/(a+ c) Proportion of those who actually have disease and are correctly identified with
positive test results. TP rate
High sensitivity = few FNs
Specificity d/(b + d) Proportion of those who do not actually have the disease who are correctly
identified with negative test results. 1–FP rate
High specificity = few FPs
PPV a/(a+ b) The proportion of those with positive test results who actually have the disease
NPV d/(c + d) The proportion of those with negative test results who do not have the disease
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The use of a 2 × 2 tables requires that the test results are dichotomous, that is, they can be divided into
two groups: test positive and test negative.
Receiver operating characteristic curve
When an intervention test has a range of possible thresholds that could be used to divide results into test
positive and test negative, the relationship between the threshold used and the performance of the test
can be examined in a receiver operating characteristic curve. This is a graphical plot of the sensitivity (TP
rate) against 1 – specificity or the FP rate for each threshold; examples of a receiver operating characteristic
curve are shown in Figure 5, with the associated distribution of the index tests in diseased and non-
diseased populations. An ideal test would have a point in the top-left corner with 100% specificity and
100% sensitivity.
Area under a receiver operating characteristic curve
The receiver operating characteristic curve can be used to assess the degree to which sensitivity changes at
different levels of specificity or vice versa. Some studies report AUC as a proportion of the total area of the
graph. This is a measure of the predictive accuracy or discrimination of the diagnostic test, that is, the
ability of the test to discriminate between those who have (or will develop) MCI from those who do not
have (or will not develop) MCI.
The AUC can also be expressed as the probability that someone with the disease will have a higher test
result than someone without the disease. It is also referred to as the c-statistic. An AUC of 1.0 indicates a
perfect test, and an AUC of 0.5 (the diagonal line) indicates that the test is no better than chance (i.e.
50% probability) in predicting whether or not the disease is present. An AUC of 0.5 to 0.7 is considered
as poor discrimination, 0.7 to 0.8 acceptable discrimination, 0.8 to 0.9 excellent discrimination and > 0.9
exceptional discrimination.
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FIGURE 5 Examples of a receiver operating characteristic curve. (Image reproduced from Cochrane Handbook for
Systematic Reviews of Diagnostic Test Accuracy with permission.107)
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Positive predictive value and negative predictive value
The PPV is the probability that subjects with a positive screening test truly have the disease.
PPV = number of TPs=number of TPs + number of FPs: (1)
The NPV is the probability that subjects with a negative screening test truly do not have the disease.
NPV = number of TNs=number of TNs + number of FNs: (2)
The PPV and NPV are clinically significant, as they give probabilities that an individual is truly MCI/early
dementia positive given that they tested positive or truly MCI/early dementia negative given that they
tested negative.
Likelihood ratio
The LR gives another measure of performance for the disease, and is described in chapter 10 of the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy,107 as follows:
The LR+ describes how many times more likely positive index test results were in the diseased group than
in the non-diseased group. The LR+, which should be > 1 if the test informative, is defined as:
LR + = P(T + jD + )=P(T + jD−) = sens= (1−spec), (3)
(where T+ is index test positive, T– is index text negative, D+ is diseased, D– is non-diseased, P means
probability and j means ‘given that’ or ‘on condition that’) and is estimated as:
½a= (a + c)= ½b= (b + d). (4)
The LR– describes how many times less likely negative index test results were in the diseased group than in
the non-diseased group. The LR–, which should be < 1 if the test is informative, is defined as:
LR− = P(T−jD + )=P(T−jD−) = (1−sens)=spec, (5)
and is estimated as:
½c= (a + c)= ½d= (b + d). (6)
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Appendix 2 Search strategies
A draft search strategy for MEDLINE was prepared and run on 15 July 2015 as part of the scopingsearches. The search was updated on 6 August 2015 alongside a search of additional databases.
The search strategies for each database are reported in Tables 19–22 and Boxes 1–4.
TABLE 19 Search strategy conducted in MEDLINE
Search terms Results
1 exp mild cognitive impairment/ 3249
2 ((early* or onset* or initial* or young* or incipient*) adj2 (dementia* or Alzheimer* or AD)).tw. 9646
3 ((Mild* or early* or onset* or initial* or progress* or minor or young* or moderat* or suspect*) adj2
Cognit* adj1 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct*
or degenerat* or deficit*)).tw.
11,933
4 MCI.tw. 11,603
5 NCD.tw. 1233
6 ((memory* or neurocognitiv*) adj2 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or
complain* or dysfunct* or degenerat* or deficit*)).tw.
29,085
7 (“preclinical alzheimer*” or “pre-clinical alzheimer*”).tw. 293
8 (prodrom* adj2 dement*).tw. 84
9 *dementia/ or *alzheimer disease/ or *dementia, vascular/ or *dementia, multi-infarct/ or
*frontotemporal dementia/
88,482
10 or/1-9 129,676
11 ((computer* or automate*) adj2 (test* or assess* or evaluat* or screen* or battery or monitor* or
identif* or assess* or evaluat* or interpret*)).tw.
19,607
12 (automat* adj2 (interpretat* or test*)).tw. 2445
13 *Neuropsychological Tests/ 13,160
14 ((neuropsychological or neuro-psychological or psychometric*) adj5 (computer* or automate*) adj5
(test* or assess* or evaluat* or screen* or battery or monitor* or identif* or assess* or evaluat* or
interpret*)).tw.
831
15 psychometrics/ 58,160
16 or/11-15 87,870
17 10 and 16 5551
18 Diagnosis, Computer-Assisted/ 19,850
19 ((computer* or automate*) adj4 (diagnos* or detect*)).tw. 13,645
20 or/18-19 30,836
21 10 and 20 366
22 disease progression/ 114,210
23 ((test* or assess* or evaluat* or screen* or battery or monitor* or identif* or assess* or evaluat* or
interpret*) adj3 diseas* adj3 (progress* or exacerbat*)).tw.
4249
24 or/22-23 117,390
25 17 and 24 342
continued
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TABLE 19 Search strategy conducted in MEDLINE (continued )
Search terms Results
26 “cambridge Neuropsychology Test*”.tw. 0
27 Computerised Neuropsychological Test Battery.tw. 38
28 Six Item Cognitive Impairment Test.tw. 11
29 “Computer Assessment of Mild Cognitive Impairment”.tw. 3
30 MindStream*.tw. 27
31 “Mild Cognitive Impairment Screen*”.tw. 11
32 Computer Administered Neuropsychological Screen for Mild Cognitive Impairment.tw. 2
33 Automated Neuropsychological Assessment Metrics.tw. 90
34 CANS-MCI.tw. 2
35 “CNS Vital Signs”.tw. 33
36 Cognitive Drug Research Computerised Assessment System for Dementia.tw. 1
37 CogState.tw. 93
38 “Cognitive Stability Index*”.tw. 6
39 “Cognitive Screening Test*”.tw. 183
40 Microcog.tw. 28
41 (COGDRAS-D or COGDRASD or COGDRAS).tw. 0
42 MCIS.tw. 167
43 (CAMCI or CNTB).tw. 20
44 6CIT.tw. 11
45 (CANTAB-A or CANTABA or CANTAB).tw. 343
46 ANAM.tw. 128
47 CADi2.tw. 1
48 or/26-46 1103
49 17 or 21 or 25 or 48 6733
50 animals/ not humans/ 3,996,470
51 49 not 50 6691
52 comment/ or editorial/ or letter/ 1,496,207
53 case reports/ 1,764,849
54 (comment or editorial or letter or journal correspondence or opinion).pt. 1,496,207
55 or/52-54 3,069,853
56 51 not 55 6360
57 limit 56 to yr=“2005 -Current” 3779
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TABLE 20 Search strategy conducted in EMBASE
Searches Results
1 exp mild cognitive impairment/ 12,572
2 ((early* or onset* or initial* or young* or incipient*) adj2 (dementia* or Alzheimer* or AD)).tw. 12,911
3 ((Mild* or early* or onset* or initial* or progress* or minor or young* or moderat* or suspect*) adj2
Cognit* adj1 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct*
or degenerat* or deficit*)).tw.
18,245
4 MCI.tw. 18,975
5 NCD.tw. 1481
6 ((memory* or neurocognitiv*) adj2 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or
complain* or dysfunct* or degenerat* or deficit*)).tw.
38,383
7 (“preclinical alzheimer*” or “pre-clinical alzheimer*”).tw. 374
8 (prodrom* adj2 dement*).tw. 124
9 *dementia/ or *alzheimer disease/ or *dementia, vascular/ or multiinfarct dementia/ or *frontotemporal
dementia/
125,217
10 or/1-9 181,482
11 ((computer* or automate*) adj2 (test* or assess* or evaluat* or screen* or battery or monitor* or
identif* or assess* or evaluat* or interpret*)).tw.
24,195
12 (automat* adj2 (interpretat* or test*)).tw. 3310
13 *Neuropsychological Test/ 6554
14 ((neuropsychological or neuro-psychological or psychometric*) adj5 (computer* or automate*) adj5
(test* or assess* or evaluat* or screen* or battery or monitor* or identif* or assess* or evaluat* or
interpret*)).tw.
1174
15 psychometry/ 46,698
16 or/11-15 76,781
17 10 and 16 3845
18 computer assisted diagnosis/ 36,170
19 ((computer* or automate*) adj4 (diagnos* or detect*)).tw. 16,191
20 or/18-19 48,801
21 10 and 20 503
22 disease course/ 323,960
23 ((test* or assess* or evaluat* or screen* or battery or monitor* or identif* or assess* or evaluat* or
interpret*) adj3 diseas* adj3 (progress* or exacerbat*)).tw.
6175
24 or/22-23 326,786
25 17 and 24 215
26 “cambridge Neuropsychology Test*”.tw. 0
27 Computerised Neuropsychological Test Battery.tw. 50
28 Six Item Cognitive Impairment Test.tw. 14
29 “Computer Assessment of Mild Cognitive Impairment”.tw. 4
30 MindStream*.tw. 76
31 “Mild Cognitive Impairment Screen*”.tw. 17
continued
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TABLE 20 Search strategy conducted in EMBASE (continued )
Searches Results
32 Computer Administered Neuropsychological Screen for Mild Cognitive Impairment.tw. 3
33 Automated Neuropsychological Assessment Metrics.tw. 120
34 CANS-MCI.tw. 4
35 “CNS Vital Signs”.tw. 63
36 Cognitive Drug Research Computerised Assessment System for Dementia.tw. 1
37 CogState.tw. 232
38 “Cognitive Stability Index*”.tw. 10
39 “Cognitive Screening Test*”.tw. 288
40 Microcog.tw. 33
41 (COGDRAS-D or COGDRASD or COGDRAS).tw. 1
42 MCIS.tw. 257
43 (CAMCI or CNTB).tw. 33
44 6CIT.tw. 22
45 (CANTAB-A or CANTABA or CANTAB).tw. 626
46 ANAM.tw. 199
47 CADi2.tw. 1
48 or/26-46 1917
49 17 or 21 or 25 or 48 5930
50 nonhuman/ not human/ 3,604,816
51 49 not 50 5870
52 comment/ or editorial/ or letter/ 1,363,574
53 case reports/ 2
54 (comment or editorial or letter or journal correspondence or opinion).pt. 1,375,197
55 or/52-54 1,407,178
56 51 not 55 5756
57 limit 56 to yr=“2005 -Current” 4134
58 limit 57 to embase 3228
59 remove duplicates from 58 3191
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TABLE 21 Number of studies retrieved from different databases
Databases Date searched Version/files Number retrieved
Cochrane Database of
Systematic Reviews
(via Cochrane)
6 August 2015 Issue 7 of 12, July 2015 684
Database of Abstracts of
Reviews of Effects
(via Cochrane)
6 August 2015 Issue 7 of 12, July 2015 32
HTA database (via Cochrane) 6 August 2015 Issue 7 of 12, July 2015 4
Cochrane Central Database
of Controlled Trials
(via Cochrane)
6 August 2015 Issue 7 of 12, July 2015 1136
NHS Economic Evaluation
Database
6 August 2015 Issue 7 of 12, July 2015 7
MEDLINE (via Ovid) and
MEDLINE In-Process & Other
Non-Indexed Citations
(via Ovid)
6 August 2015 Ovid MEDLINE(R) 1946 to week 5 July 2015,
Database Field Guide Ovid MEDLINE(R)
In-Process & Other Non-Indexed Citations
5 August 2015
3779
EMBASE (via Ovid) 6 August 2015 1980 to 2015 Week 31 3191
Web of Science 6 August 2015 N/A 3586
PsycINFO 6 August 2015 N/A 541
PubMed 3 September 2015 N/A 392
ProQuest theses and
dissertations
3 September 2015 N/A 197 (main search);
1919 (search for
test names)
Hand-searching 26 August 2015 N/A 4
Citation tracking 19 September 2015 N/A 3324
TABLE 22 Hand-searching for trials
Databases Date searched Links to results
ClinicalTrials.gov 26 August 2015 A Study of a Self-Administered Memory Screening Test With
Automated Reporting (SAMSTAR) in Participants With Mild
Cognitive Impairment64
Pilot Testing a New Computer-based Screening Tool to Detect
Cognitive Impairment65
Feasibility and Validity of A Novel Computer Based Battery of
Assessments in the Elderly (HHT)66
Computational Tools for Early Diagnosis of Memory Disorders
(ProsKuopio)67
metaRegister of Controlled Trials and
ISRCTN Register
26 August 2015 None found
World Health Organization
International Clinical Trials Registry
Platform
26 August 2015 None found
PROSPERO systematic review register 26 August 2015 None found
Epistemonikos 26 August 2015 No new references found
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BOX 1 Search strategy conducted in PsycINFO
Strategy used
TI “Cognitive Stability Index*” OR TI “Cognitive Screening Test*” OR TI Microcog OR TI ( (COGDRAS-D or
COGDRASD or COGDRAS) ) OR TI MCIS OR TI ( (CAMCI or CNTB) ) OR TI 6CIT OR TI ( (CANTAB-A or
CANTABA or CANTAB) ) OR TI ANAM OR TI CADi2
TI “cambridge Neuropsychology Test*” OR TI Computerised Neuropsychological Test Battery OR TI Six Item
Cognitive Impairment Test OR TI “Computer Assessment of Mild Cognitive Impairment” OR TI MindStream*
OR TI “Mild Cognitive Impairment Screen*” OR TI Computer Administered Neuropsychological Screen for Mild
Cognitive Impairment OR TI Automated Neuropsychological Assessment Metrics OR TI CANS-MCI OR TI “CNS
Vital Signs” OR TI Cognitive Drug Research Computerised Assessment System for Dementia OR TI CogState
TI ( ((early* or onset* or initial* or young* or incipient*) near2 (dementia* or Alzheimer* or AD)) ) OR TI
( ((Mild* or early* or onset* or initial* or progress* or minor or young* or moderat* or suspect*) near2 Cognit*
near1 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct* or degenerat*
or deficit*)) ) OR TI ( MCI or NCD ) OR TI ( ((memory* or neurocognitiv*) near2 (impair* or disord* or diseas*
or declin* or deteriorat* or fail* or complain* or dysfunct* or degenerat* or deficit*)) ) OR TI ( (“preclinical
alzheimer*” or “pre-clinical alzheimer*”) ) OR TI (prodrom* near2 dement*) AND TI ( ((computer* or
automate*) near4 (diagnos* or detect*)) )
TI ( ((early* or onset* or initial* or young* or incipient*) near2 (dementia* or Alzheimer* or AD)) ) OR TI
( ((Mild* or early* or onset* or initial* or progress* or minor or young* or moderat* or suspect*) near2 Cognit*
near1 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct* or degenerat*
or deficit*)) ) OR TI ( MCI or NCD ) OR TI ( ((memory* or neurocognitiv*) near2 (impair* or disord* or diseas*
or declin* or deteriorat* or fail* or complain* or dysfunct* or degenerat* or deficit*)) ) OR TI ( (“preclinical
alzheimer*” or “pre-clinical alzheimer*”) ) OR TI (prodrom* near2 dement*) AND TI ( ((computer* or
automate*) near2 (test* or assess* or evaluat* or screen* or battery or monitor* or identif* or assess* or
evaluat* or interpret*)) ) OR TI ( (automat* near2 (interpretat* or test*)) ) OR TI ( ((neuropsychological
or neuro-psychological or psychometric*) near5 (computer* or automate*) near5 (test* or assess* or evaluat*
or screen* or battery or monitor* or identif* or assess* or evaluat* or interpret*)) )
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BOX 2 Search strategy conducted in Web of Science
Strategy used
TITLE: (((early* or onset* or initial* or young* or incipient*) near2 (dementia* or Alzheimer* or AD))) OR
TITLE:(((Mild* or early* or onset* or initial* or progress* or minor or young* or moderat* or suspect*) near2
Cognit* near1 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct* or
degenerat* or deficit*))) OR TITLE: (MCI or NCD)OR TITLE: (((memory* or neurocognitiv*) near2 (impair* or
disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct* or degenerat* or deficit*)))OR
TITLE: ((“preclinical alzheimer*” or “pre-clinical alzheimer*”)) ORTITLE: ((prodrom* near2 dement*))OR
TITLE: (*dementia/ or *alzheimer disease/ or *dementia, vascular/ or *dementia, multi-infarct/ or
*frontotemporal dementia/) ANDTITLE: (Diagnosis, Computer-Assisted/) OR TITLE: (((computer* or automate*)
near4 (diagnos* or detect*)))
Refined by: PUBLICATION YEARS: ( 2013 OR 2011 OR 2014 OR 2010 OR 2009 OR 2012 OR 2005 OR 2008
OR 2007 OR 2006 OR 2015 )
TITLE: (((early* or onset* or initial* or young* or incipient*) near2 (dementia* or Alzheimer* or AD))) OR
TITLE:(((Mild* or early* or onset* or initial* or progress* or minor or young* or moderat* or suspect*) near2
Cognit* near1 (impair* or disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct* or
degenerat* or deficit*))) OR TITLE: (MCI or NCD)OR TITLE: (((memory* or neurocognitiv*) near2 (impair* or
disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct* or degenerat* or deficit*)))OR
TITLE: ((“preclinical alzheimer*” or “pre-clinical alzheimer*”)) ORTITLE: ((prodrom* near2 dement*))OR TITLE:
(*dementia/ or *alzheimer disease/ or *dementia, vascular/ or *dementia, multi-infarct/ or *frontotemporal
dementia/) ANDTITLE: (((computer* or automate*) near2 (test* or assess* or evaluat* or screen* or battery or
monitor* or identif* or assess* or evaluat* or interpret*))) OR TITLE: ((automat* near2 (interpretat* or test*)))
ORTITLE: (((neuropsychological or neuro-psychological or psychometric*) near5 (computer* or automate*)
near5 (test* or assess* or evaluat* or screen* or battery or monitor* or identif* or assess* or evaluat*
or interpret*)))
Refined by: PUBLICATION YEARS: ( 2013 OR 2011 OR 2014 OR 2010 OR 2009 OR 2012 OR 2005 OR 2008
OR 2007 OR 2006 OR 2015 )
TITLE:(“cambridge Neuropsychology Test*”) OR TITLE: (Computerised Neuropsychological Test Battery)
ORTITLE: (Six Item Cognitive Impairment Test) OR TITLE:(“Computer Assessment of Mild Cognitive
Impairment”) OR TITLE:(MindStream*) OR TITLE: (“Mild Cognitive Impairment Screen*”) ORTITLE: (Computer
Administered Neuropsychological Screen for Mild Cognitive Impairment) OR TITLE:(Automated
Neuropsychological Assessment Metrics) OR TITLE:(CANS-MCI) OR TITLE: (“CNS Vital Signs”) OR TOPIC:
(Cognitive Drug Research Computerised Assessment System for Dementia) OR TITLE:(CogState) OR TITLE:
(“Cognitive Stability Index*”) OR TITLE:(“Cognitive Screening Test*”) ORTITLE: (Microcog) OR TITLE:
((COGDRAS-D or COGDRASD or COGDRAS)) OR TITLE: (MCIS) ORTITLE: ((CAMCI or CNTB)) ORTITLE: (6CIT)
OR TITLE: ((CANTAB-A or CANTABA or CANTAB)) ORTITLE: (ANAM) OR TITLE: (CADi2)
Refined by: PUBLICATION YEARS: ( 2014 OR 2012 OR 2005 OR 2013 OR 2007 OR 2006 OR 2010 OR 2009
OR 2011 OR 2015 OR 2008 )
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BOX 3 Search strategy conducted in PubMed
Strategy used
SearchAdd to builderQueryItems foundTime#10AddSearch (#8 and #9)39206:19:55#9AddSearch (“2015/03/
03”[Date - Entrez] : “3000”[Date - Entrez])55757506:09:00#8AddSearch (#3 or #5 or #6)
780906:08:27#7AddSearch (#3 and #5 and #6)38906:07:46#6AddSearch (((((((((((((((((((((“cambridge
Neuropsychology Test*”) OR Computerised Neuropsychological Test Battery) OR Six Item Cognitive Impairment
Test) OR “Computer Assessment of Mild Cognitive Impairment”) OR MindStream*) OR “Mild Cognitive
Impairment Screen*”) OR Computer Administered Neuropsychological Screen for Mild Cognitive Impairment)
OR Automated Neuropsychological Assessment Metrics) OR CANS-MCI) OR “CNS Vital Signs".) OR Cognitive
Drug Research Computerised Assessment System for Dementia) OR CogState) OR “Cognitive Stability Index*”)
OR “Cognitive Screening Test*”) OR Microcog) OR (COGDRAS-D or COGDRASD or COGDRAS)) OR MCIS) OR
((CAMCI or CNTB))) OR 6CIT) OR ((CANTAB-A or CANTABA or CANTAB))) OR ANAM) OR
CADi2395306:06:42#5AddSearch (#1 and #4)266706:03:29#4AddSearch ((computer* or automate*)) AND
(diagnos* or detect*)20789406:03:01#3AddSearch (#1 and #2)352806:02:34#2AddSearch (((((((computer* or
automate*)) AND (test* or assess* or evaluat* or screen* or battery or monitor* or identif* or assess* or
evaluat* or interpret*)) OR automat*) AND (interpretat* or test*)) OR (neuropsychological or neuro-
psychological or psychometric*)) AND (computer* or automate*)) AND (test* or assess* or evaluat* or screen*
or battery or monitor* or identif* or assess* or evaluat* or interpret*)15364006:01:47#1AddSearch ((((((((early*
or onset* or initial* or young* or incipient*)) AND (dementia* or Alzheimer* or AD)) OR (Mild* or early* or
onset* or initial* or progress* or minor or young* or moderat* or suspect*)) AND Cognit*) AND (impair* or
disord* or diseas* or declin* or deteriorat* or fail* or complain* or dysfunct* or degenerat* or deficit*)) AND
(MCI OR NCD)) OR (memory* or neurocognitiv*)) AND (impair* or disord* or diseas* or declin* or deteriorat*
or fail* or complain* or dysfunct* or degenerat* or deficit*)11603206:00:22
BOX 4 Search strategy conducted in ProQuest
Strategy used
“cambridge Neuropsychology Test*” OR (“Computerised Neuropsychological Test Battery” OR “Six Item
Cognitive Impairment Test”) OR (“Computer Assessment of Mild Cognitive Impairment” OR (CANTAB-A or
CANTABA or CANTAB)) OR (“Mild Cognitive Impairment Screen*” OR “Computer Administered
Neuropsychological Screen for Mild Cognitive Impairment”) OR (“Automated Neuropsychological Assessment
Metrics” OR CANS-MCI) OR (“CNS Vital Signs” OR “Cognitive Drug Research Computerised Assessment
System for Dementia”) OR (CogState or microcog OR “Cognitive Stability Index*”) OR (“Cognitive Screening
Test*” OR (CAMCI or CNTB)) OR ((COGDRAS-D or COGDRASD or COGDRA) OR MCIS or 6CIT or ANAM or
CADi2 or MindStream*) AND (dementia or alzheimers or MCI OR “Mild cognitive impairment”)
((early* OR onset* OR initial* OR young* OR incipient*) NEAR/2 (dementia* OR Alzheimer* OR AD)) AND
(((computer* or automate*) near/2 (test* or assess* or evaluate* or screen* or battery or monitor* or identif*
or ssess* or evaluate* or interpret*)) OR (automat* near/2 (interpret* or test*)) )
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Appendix 3 Studies excluded, with reasons
The full list of excluded studies is available from the authors.
Reason for exclusion Number of studies
Exclusion reason: paper-based test 116
Exclusion reason: wrong study design 59
Exclusion reason: not an evaluation of the automated test 31
Exclusion reason: wrong patient population 32
Exclusion reason: systematic review 23
Exclusion reason: literature review 20
Exclusion reason: wrong intervention 16
Exclusion reason: wrong indication – other 55
Exclusion reason: wrong outcome 9
Exclusion reason: wrong outcomes; continuous data 6
Exclusion reason: automated test not in English 9
Exclusion reason: timeline 4
Exclusion reason: duplicate 3
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Appendix 4 Names of all of the tests identified
Test Paper or computer or other
ANAM Computer
Automated Cognitive Test Computer
Automated Neuropsychological Assessment Metrics Computer
CADi2 Computer
CAMCI Computer
CANTAB Computer
Central Nervous System Vital Signs Brief Clinical Evaluation Battery Computer
CNS vital signs Computer
CNTB Computer
COAD Computer
COGDRAS-D Computer
Cognitive Drug Research Computerised Assessment System for Dementia Computer
CogState MCI/AD battery Computer
Community Screening Instrument for Dementia Computer
Computer Assessment of MCI Computer
Computer Self Test Computer
Computer-Administered Neuropsychological Screen for MCI Computer
CSI Computer
CST Computer
Dr Oz Computer
Florida Brief Memory Scale Computer
GrayMatters Assessment System Computer
Groton Maze Learning Test Computer
IntegNeuro and WebNeuro Computer
MCIS Computer
MCI Screen Computer
MicroCog Computer
Mindstreams Computer
NeuroTrax Computer
Nonverbal Medical Symptom Validity Test Computer
Poon-Baro-Wens Computer
TDAS Computer
TPSP Computer
Scenery Picture Memory Test Other
Sweet 16 Other
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Test Paper or computer or other
3MS Paper
3TD Paper
6CIT Paper
AD8 Paper
ADAS-COG Paper
Albert Einstein Health Self-Assessment Form Paper
Animal Naming Test Paper
BDRS Paper
BEHAVE-AD Paper
Benton Fluency Test Paper
CAMCOG Paper
CAMDEX Paper
CERAD Paper
CERAD-BRSD Paper
Clock Drawing Test Paper
Cued-Recall Retrieval Speed Task Paper
GPCOG Paper
Hopkins Verbal Learning Test-Revised Paper
KICA-Cog Paper
MIS Paper
MMSE Paper
MoCA Paper
National Institutes of Health Toolbox Paper
Neuropsychological Test Battery Paper
Nishimura Mental State Paper
NPI-NH Paper
PAS Paper
PBAC Paper
RBANS Paper
RUDAS Paper
SIS Paper
SLUMS Paper
Social Cognition and Emotional Assessment Paper
The Mini-Kingston Standardized Cognitive Assessment Paper
Trail Making Test Paper
Verbal Category Cued Memory Test Paper
Verbal Fluency Test Paper
Wechsler Adult Intelligence Scale Paper
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Test Paper or computer or other
Cognistat Paper/computer
MOST Paper/computer
Rey-Osterrieth Figure Copy Paper/computer
CUSPAD Paper/other
3MS, Modified Mini-Mental State; 3TD, Treatment Target Test Dementia; 6CIT, Six-Item Cognitive Impairment Test;
ADAS-COG, Alzheimer’s Disease Assessment Scale; ANAM, Automated Neuropsychological Assessment Matrix; BDRS, Blessed
Dementia Rated Scale; BEHAVE-AD, Behavioural Pathology in Alzheimer’s Disease; CADi2,Cognitive Assessment for Dementia,
iPad Version; CAMCOG, Cambridge Cognitive Examination; CAMDEX, Cambridge Mental Disorders of the Elderly Examination;
CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CNTB, Computerized Neuropsychological Test Battery;
COAD, Computerised Object and Abstract Designs; COGDRAS-D, Cognitive Drug Research Computerized Assessment
System for Dementia Patients; CSI, Cognitive Stability Index; GPCOG, General Practitioner Assessment of Cognition;
KICA-Cog, Kimberley Indigenous Cognitive Assessment; MCIS, Mild Cognitive Impairment Screen; MIS, Memory Impairment
Screen; MoCA, Montreal Cognitive Assessment; MOST, Memory Orientation Screening Test; NPI-NH, Neuropsychiatric
Inventory Nursing Home Version; PAS, Psychogeriatric Assessment Scale; PBAC, Philadelphia Brief Assessment of Cognition;
RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; RUDAS, Rowland Universal Dementia Assessment
Scale; SIS, Six-Item Screener; SLUMS, Saint Louis University Mental Status; TDAS, Touch Panel-type Dementia Assessment Scale.
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Appendix 5 Patient and public involvement:
structure of meeting
B rief chat, any difficulties with train trip, any questions he may have. Check for comfort with recordingdevice, assure recording will be deleted. If not, use tablet for quick typing. He mentioned his caring
responsibilities. Talk slowly, pay attention to ability to retain and analyse information. Simple language.
What is LRiG. Overview of the project. Brief discussion background MCI and dementia. Explain the review
process very briefly.
Intro questions from protocol.
l Was the purpose of the review clear?
l Was the purpose of the review appropriate/valid/important?
Questions relating to technology.
Explain what computerised tests are briefly. Compare to tests used in his and/or carer’s diagnosis.
(a) About the tests (show table on test, discuss table, clarify, make sure it is understood)
– Different types of tests (show table), some tests look at 1–2 aspects of memory and thinking,
others look at all aspects of memory and thinking (cognitive domains).
– 2 tests look at the visual aspect (PAL), and make an assessment with a clinician present about
existence of challenges with memory and thinking.
– Our findings say it works well. Does he have any thoughts about this?
(b) Platform used
– Internet-based test, iPad versus computer touchscreen versus desktop. Rating 1–4.
– Comfort in using platform (create flow from previous questions so would talk about use of
technology in the elderly).
(c) Professionals involved
– Different papers used professionals differently.
– For test administration it was (1) self-administered with minimum assistance with nurse or
technician; (2) self-administered with minimum assistance with nurse or technician, which also
included them typing or using the mouse to manipulate the mouse or arrows for the patient or
facilitate the typing and entering of patient responses; (3) verbal directions from administration;
(4) interactive system provided oral instruction through speakers and written instructions on
screen; (5) self-administration, but carer can assist needed them typing or using the mouse to
manipulate the mouse or arrows for the patient or facilitate the typing and entering of
patient responses.
– Rate tests from 1–5 with 1 being most preferable. Enter sixth option manually if a combination.
– Feedback on professionals conducting the test (who).
– What did he think of the level of involvement of the assessor in these scenarios in conducting
the tests?
– What about monitoring?
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(d) Patient characteristics
– Disease progression, do they go to the doctor
– Follow-up
– Study sample
– Where people were recruited from
– Only included patients (summary and variance of inclusion criteria)
– Summary of age, gender, education, ethnicity (race).
(e) Follow-up questions in the end
– Do we report on all of the important aspects of the research (show tables) (e.g. age of
participants, practicality of computer tests for this age group)?
– Was the purpose of the review clear?
– Was the purpose of the review appropriate/valid/important?
– What do they see as the implications for clinical practice?
– What value do you see in the use of diagnostic tests for MCI?
– Do you feel that the inclusion of computerised tests is a good one?
– Should they be used instead of pen-and-paper tests?
– When do you think they should be used?
– What areas need further research?
APPENDIX 5
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Appendix 6 Organisations approached for service
user involvement
l Liverpool Service User Reference Forum for Dementia.
l North West People in Research Forum.
l Salford Citizen Scientist – Francine Jury at People In Research Involve.
l Join Dementia Research – National Institute for Health Research.
l Dementias and Neurodegeneration National Institute for Health Research Clinical Research Network.
l National Institute for Health Research Clinical Research Network for Ageing.
l The Alzheimer’s Society.
Using Twitter (Twitter Inc., San Francisco, CA, USA; www.twitter.com), we also sent out mass tweets to 72
other relevant organisations.
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Appendix 7 Sample letter sent to organisations
to invite service users
Advisory group members: computer based tests for mild
cognitive impairment and dementia
By Aslam, 19 August 2015.
Do you want to get involved in research to find out whether computer-based tests for assessing a person’s
memory and thinking work?
The Liverpool Reviews and Implementation Group specialises in using a research method called a
systematic review of the literature. This method provides an overview of the relevant research in the
subject area.
The Liverpool Reviews and Implementation Group is currently working on a research project funded by the
National Institute for Health Research. They are currently looking for people living with mild cognitive
impairment (MCI) or early dementia as well as their carers who have an interest in assessment tools for
thinking and memory.
As part of the research process, they would like to form an advisory group. The advisory group will have
2–3 service users or carers who have an interest in assessment tools for thinking and memory. The advisory
group would be expected to attend two meetings between August 2015 and December 2015, and will
need to be available for consultation via e-mail or face to face between meetings. They will pay a fee for
consultation and travel expenses for all meetings. To apply, please complete the application form and
return to the Liverpool Reviews and Implementation Group.
For more information contact:
Dr Rabeea’h Waseem Aslam, Liverpool Reviews and Implementation Group, University of Liverpool.
Telephone: XXX
E-mail: XXX
Deadline: 20 September 2015.
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